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Ku70 is a protein with multiple biological functions. It is well-known 
that Ku70 forms heterodimer with Ku80 and is essential for the repair of 
nonhomologous DNA double-strand breaks. Recent studies showed that the 
acetylation of Ku70 is a master switch in the apoptotic pathway. Therefore, 
Ku70 might be a therapeutic target for cancer treatment, and it is important to 
thoroughly study the Ku70 protein complex to unravel its biological functions. 
We employed mass spectrometry based proteomic methods to characterize the 
Ku70 protein complex. As proteomics is still in its infancy stage, we have 
developed novel effective peptide purification and concentration method for 
in-gel digestion sample in order to drill down to the details of the Ku70 
complex by identification of both strong and weak binding partners.  In 
addition, we have adapted one step FLAG-tag purification and two steps 
tandem affinity purification (TAP) methods to purify the Ku70 protein 
complex. The FLAG-tag and TAP-tag were fused in-frame to Ku70 gene and 
the tagged-Ku70 fusion proteins expressed in 293F cell were used as bait to 
pull down its interacting partners. The pulled-down complex was analyzed by 
both SDS-PAGE coupled to MALDI-TOF/TOF-MS and shotgun LC-MS/MS 
proteomics approaches. Epitope-tag based purification strategies enable 
protein complex to be isolated with exceptional purity and eliminated 
background of non-specific binding proteins. As a result, it has significantly 
improved the outcome of mass spectrometry-based protein complex 
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characterization and enables identification of weak interaction partners. 
Consequently, 151 proteins were characterized in Ku70 protein complexes. 
These proteins play a diverse range of biological functions from DNA repair 
to transcriptional regulation to cellular signal mediator. Among these, 20 are 
known Ku70 interacting proteins, they function mainly in DNA repairs and 
telomeric maintenance. Others are mainly cytosolic proteins that are classified 
to be apoptotic regulatory proteins or signal transduction proteins by Panther 
gene ontology database. These are consistent with the recent reported Ku70 
functions in regulating cellular apoptosis. As Ku70 acetylation has been 
reported to be a pivotal post translational modification that regulates Ku70 
activities, we finally identified the potential acetylation sites of Ku70 by both 
in vivo and in vitro acetylation analysis. We are working to further 
characterize the Ku70 complex by biochemical assays to understand its role in 
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              The completion of the genome sequences of the human and many 
other organisms is undoubtedly a big step towards the full understanding of 
biological sciences. The availability of enormous amount of data in the 
genome and the expressed sequence tag (EST) databases opens new avenues 
to analyze protein functions and leads us to the post-genomic era. Proteomics, 
the global analysis of proteins, is a new field of research in the post-genomics 
era.  As proteins are the functional molecules that control the living process, 
from structural elements, to catalysts, to signaling messengers and gene 
regulatory transcription factors, proteomics data will provide rich information 
to unravel how living systems work at the molecular level.   
              Proteins do not act alone. They usually form protein complexes to 
exert different functions and transmit different signals. All the biological 
activities depend upon direct physical interaction of specific cellular proteins. 
Each protein in living matter functions as part of an extended web of 
interacting molecules. The classic view of protein function focuses on the 
action of a single protein molecule. However, to truly understand a 
multifunctional protein, the isolated study of individual protein is not enough 
and thorough. The pull down of protein complex in a given cell or tissue at a 
defined condition will then provide a detailed information about the 
interaction partners of a specific protein in a certain state. The interaction 
partners will reveal the functions of the target protein.  With the availability of 
various databases such as Gene Ontology (GO) or Panther which collect all 
the known molecular functions of proteins and group them to pathways and 
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biological processes, the functions of target protein can be classified to 
functional pathways and biological processes by interrogating the set of pull 
down proteins with these databases. 
              In characterizing binding partners for a molecule of interest, the 
quality of the purified protein complex plays a critical role in the ultimate 
success of the experiment. Classical biochemical purification methods rely 
heavily on the biophysical properties of a given protein, for example, a typical 
immunoprecipitation (IP). However, most antibodies usually cross-react with 
many irrelevant proteins, thus generate significant background. Although it 
will not interfere with the traditional biochemical assays such as Western 
blotting which only probes for the presence of one specific protein,  it will 
generate significant false positive results when the pull down sample is 
analyzed by mass spectrometry method which unselectively identifies all 
proteins in the sample. To circumference the problem of nonspecific binding 
contaminants, affinity purification procedures utilizing epitoge-tag or two 
consecutive epitope tags - tandem affinity purification (TAP) steps have been 
developed and proven to be highly effective in the identification of protein 
complexes. In this tandem affinity purification (TAP) method, two affinity 
tags with orthogonal purification properties such as IgG-binding domain of 
protein A of Staphylococcus aureus (ProtA) and calmodulin-binding peptide 
(CBP) are inserted into a vector. The protein of interest is fused to the TAP tag 
and expressed in the organism or cell line under investigation. The two TAP 
tags are separated by spacer regions and a cleavage site for tobacco etch virus 
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(TEV) protease. The fusion protein and associated components are first 
recovered from cell extracts by affinity selection on an IgG matrix and eluted 
by incubation with TEV protease. The eluates which contained protein 
complexes were further purified by incubation with calmodulin coated beads 
in the presence of calcium. Highly purified protein complexes were eluted by 
depleting of calcium ions with EGTA. The two steps purification with two 
different affinity chromatographic methods minimizes the nonspecific binding 
contaminants. The whole procedure is carried out under mild, nondenaturing 
conditions that maximize the chance of isolating an intact and functional 
protein complex. 
Detecting trace amount of TAP tag purified protein complex is 
challenging.  Compared with DNA analysis, trace DNA in a sample can be 
detected by amplifying the DNA using polymerase chain reaction (PCR). A 
method for amplifying protein has not yet been developed. Mass spectrometry 
is the method of choice for protein identification and analysis because of its 
sensitivity and accuracy.  Recent development in ionization methods and 
improvement on instrumentation have significantly enhanced its performance 
in protein characterization. It has rapidly become a standard method for 
protein analysis. 
              Molecular weight is a unique property of each molecule. Mass 
spectrometry is an instrument designed to measure molecular weight 
accurately, and thus to characterize the molecule through its molecular weight. 
The application of mass spectrometry for biomolecules analysis is triggered by 
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the recent advent of electrospray ionization (ESI) and matrix-assisted laser 
desorption ionization (MALDI) methods. These soft ionization methods can 
bring the fragile biomolecule into the gas phase with charges. The molecular 
weight of the intact protein can be measured accurately by different types of 
mass analyzers such as time-of-flight (TOF), quadrupole, quadrupole ion trap, 
Orbitrap and Fourier transform ion cyclotron resonance (FTICR, also known 
as FTMS). Coupling different ionization methods to different mass analyzers 
provides a versatile set of mass spectrometry methods with surprising 
sensitivity and accuracy for protein and other biomolecular analysis. 
              The true power of mass spectrometry for protein characterization is 
the utilization of tandem mass spectrometry (MS/MS) and proteolytic 
digestion for protein sequence analysis and for the localization of post-
translational modifications. Trypsin is by far the most widely used protease in 
proteomic analysis. Trypsin cleaves proteins at lysine and arginine residues, 
unless either of these is followed by a proline residue in the C-terminal 
direction. The spacing of lysine and arginine residues in many proteins is 
distributed relatively evenly. The resulting tryptic peptides are of a length 
well-suited to MS analysis. 
              The most common MS/MS methods currently for protein 
fragmentation involve low energy fragmentation by collisionally-activated 
dissociation (CAD) or post-source decay (PSD). The sequence information is 
obtained from the generation of fragments by the cleavage of the protein 
backbone. The post translational modification of protein can be determined by  
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the shift in mass of fragments with the molecular weight of the modified 
functional group. 
              The detection of post-translational modification (PTM) is another 
important application of modern mass spectrometry. PTM represents an 
important mechanism for regulating protein function. Lysine acetylation, or 
the transfer of an acetyl group from acetyl coenzyme A to the ε-amino group 
of a lysine residue, is among the most important post-translational 
modifications. It was initially discovered on histones. But later many 
nonhistone proteins were also found to be acetylated indicating the critical role 
of this modification. This project focuses on Ku70, a protein with multiple 
functions and can be acetylated by histone acetyltransferase. The TAP 
purification and mass spectrometry analysis of Ku70 complex will be 
described and discussed in Chapter 3. The in vivo and in vitro acetylation of 
Ku70 will be discussed in Chapter 4. 
              As proteomics is still in its infancy stage, technology development is 
the key to advance the field to address more sophisticated biological questions. 
Since the success of a mass spectrometry based proteomic analysis critically 
depend on the samples quality, an optimal sample preparation is one of the 
most important factors in proteomics analysis. Particularly, the interface 
between protein digestion and mass spectrometric analysis has a large 
influence on the overall quality and sensitivity of the analysis. As salt and 
detergent are detrimental to ionization process, a typical sample preparation 
involves in-gel digestion, sample extraction and concentration, desalting and 
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elution. Solid phase extraction (SPE) is a widely used technique for the 
purification and concentration of analytes from liquid samples to improve 
sensitivity in the analytical process. Commercial tips containing 
chromatographic material polymerized into pipette tips (ZipTips, Millipore) 
have also been introduced and are widely used. However, both of them have 
some shortcomings. New methods which have large binding capacity, small 
elution volume, minimum sample lost are still under development. Here we 
developed a novel method for concentration and purification of proteolysis 
products by using small pieces of Empore Disk (3M, Minneapolis, MN). The 
Empore Disk is a particle-loaded membrane that incorporates tightly solid 
phase sorbent particles within an inert matrix of polytetrafluoroethylene. The 
high density of the particles increases the extraction efficiency and reduces the 
elution volumes. Chapter 2 will describe this newly developed method. 
 
Overview 
              This dissertation describes development and application of mass 
spectrometry based proteomics technologies to decipher Ku70 biological 
functions. We first improve the proteomics sample preparation method in 
order to enhance the sample recovery after tryptic in gel digestion. Chapter 2 
describes this newly developed method for concentration and purification of 
proteolysis products by using small pieces of Empore Disk (3M, Minneapolis, 
MN). This method has been applied to maximally recovery peptides from in-
gel and in-solution digestion. Then we generated two cell lines with stable 
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transfected FLAG and TAP tagged Ku70 in HEK293F cell respectively. 
Chapter 3 describes the tandem affinity purification and mass spectrometry 
analysis of Ku70 complex. The in vivo and in vitro acetylation analysis of 
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              In the post-genomic era, proteomics research attracts much effort to 
identify new biomarkers or targets for drug discovery. Protein identification 
by mass spectrometry plays an important role in proteomics research because 
of the sensitivity, specificity and speed of mass spectrometer. Since the 
sensitivity and accuracy of the analysis critically depend on the quality of 
sample to be analyzed by mass spectrometry, optimal sample preparation is 
one of the most critical factors for positive result in proteomics analysis. 
Particularly, the interface between protein digestion and mass spectrometric 
analysis usually determines the overall quality and sensitivity of the analysis. 
A proteome can be characterized by either shotgun proteomics 
approach with LC-MS/MS or 2D gel approach couple to mass spectrometry 
for gel spot identification. In shotgun approach, the protein mixture is first 
digested in solution to a complex peptide mixture. The peptide mixture is then 
separated by multi-dimensional liquid chromatography coupled to on-line 
electrospray ionization (ESI). Peptide ions generated by ESI are subsequently 
subjected to collision induced dissociation in tandem mass spectrometer to 
sequence the peptides. In gel approach, the protein mixture is separated by 
polyacrylamide gel electrophoresis. Proteins are detected by staining methods. 
Relevant protein bands or spots are then cut out, digested with trypsin “in gel”, 
and the resulting peptide mixtures are analyzed by MALDI-TOF-MS or LC-
MS/MS to identify the protein. 
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The peptide samples obtained by proteolysis are usually not directly 
analyzed, because they are in buffer with high concentration of salts or 
detergents that are not compatible with high-sensitivity mass spectrometric 
analysis, or the concentration of the samples are too diluted to be directly 
detected. Concentration and purification are routinely achieved by binding of 
the peptides to reversed-phase material in microcolumns or microtips. The 
peptides are then eluted off-line in one or several steps for subsequent analysis 
by mass spectrometry. 
Solid phase extraction (SPE) is a widely used technique for the 
purification and concentration of analytes from liquid samples to achieve 
increased sensitivity in the analytical process. Bonded silica sorbents are 
commonly used for the solid phase extraction of analytes from complex 
samples. A variety of functional groups, such as octadecyl (C18) and octyl (C8) 
can be bonded to the silica surface to provide non polar interactions. Each of 
these sorbents exhibits unique properties of retention and selectivity for a 
particular analyte. 
Commercial tips containing chromatographic material polymerized 
into pipette tips (ZipTips, Millipore) have been introduced and are widely used 
for concentration and purification of femtomoles to picomoles of biomolecules 
for MS analysis. The ZipTips pipette tips are simple and easy to use for single 
or few samples. However, the operation is tedious for large amount of samples. 
The need to pass the same sample through the material multiple times 
manually introduces repetitive pipetting steps. Besides their high material 
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costs, the binding properties of these tips and the required elution volumes 
have been found unsatisfactory by some researchers (Larsen et al., 2002). 
ZipTips are also not readily coupled to nanoelectrospray needles. 
Here we developed a method for concentration and purification of 
proteolysis products by using small piece of Empore Disk (3M, Minneapolis, 
MN). The Empore Disk is a particle-loaded membrane. This membrane can be 
secured into a variety of devices that offer advantages. The Empore membrane 
technology incorporates tightly solid phase sorbent particles within an inert 
matrix of polytetrafluoroethylene (90% sorbent: 10% PTFE, by weight). The 
high density of the particles increases the extraction efficiency and reduces the 
elution volumes. At the same time, the PTFE fibrils do not interfere with the 
activity of the particles in any way.  
Many C18 microspin columns were developed in recent years for the 
desalting and concentration of peptides (Rappsilber et al., 2003; Naldrett et al., 
2005; Ishihama et al., 2006). These devices are expensive and low throughput. 
We introduce here a simple, inexpensive and efficient method for peptide 
extraction from digestion buffer by C18 Empore Disk. A small piece of C18 
Empore material can be reproducibly corked out by a hollow tool, such as a 
blunt tipped hypodermic needle or a 200 μl pipette tip in exactly the same way 
that cookies are cut. One disk is sufficient for producing thousands of such 
membrane disks. Peptides in aqueous solution bind to C18 materials through 
hydrophobic interactions, allowing small interfering molecules (salts, 
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detergents) to be washed off. The peptides are then eluted with organics 
solvent that are compatible with mass spectrometry analysis.  
 
2.2 Materials and Methods 
2.2.1 In Solution Empore Disk Extraction 
              Samples with 1 picomol, 100 femtomol, 50 femtomol and 10 
femtomol commercial digested BSA peptides (MICHROM Bioresources Inc.)  
in 10μl 100mM ABB/0.1% TFA were prepared. Empore Disk C18 (3M) was 
cut manually by a 200 μl pipette tip in cookie cutter fashion. The cut-out 
Empore Disks were first wet by 100% ACN and conditioned by 100% 
methanol and then put inside the BSA peptides solution incubating for 30 
minutes at 60°C and 3 hours at room temperature. The Empore Disk was then 
washed with 200μl 0.1% TFA for 15 minutes and eluted by 2μl elution buffer 
(90% ACN, 0.1% TFA) for 1 h. In order to elute the peptides completely, the 
small piece of Empore Disk was inserted into the tip of a 200μl gel loading 
pipette tip by a capillary. The elution buffer was pressed through Empore Disk 
for 15 times by a 200μl Eppendorf pipette. The eluted peptides were mixed 
with same amount of matrix solution containing 10 mg/ml of α-cyano-4-
hydroxycinnamic acid (CHCA) in 0.1%TFA/50%ACN, and spotted onto a 
384-well stainless-steel MALDI target plate (Applied Biosystems). 
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2.2.2 SDS-polyacrylamide Gel Electrophoresis (SDS-PAGE)  
              Different amounts of standard protein BSA (Sigma) were prepared 
and run in different lanes of 7.5% polyacrylamide gel from 10 picomol, 1 
picomol, 500 femtomol, 100 femtomol, 50 femtomol, 10 femtomol, 5 
femtomol to 1 femtomol with a Mini protein II electrophoresis apparatus (Bio-
Rad Laboratories, California, USA) or on 4-12% (w/v) gradient pre-cast 
NuPAGE® Novex Bis-Tris gels (Invitrogen) with a XCell SureLock™ Mini-
Cell (Invitrogen).      
 
2.2.3 Silver Staining 
For low amount of BSA, after electrophoresis, the gels were fixed in 
fixing buffer (40% Ethanol, 10% Acetic acid and 50% H2O) and stained using 
SilverQuest Silver Staining Kit (Invitrogen) according to the manufacturer’s 
instructions. 
 
2.2.4 Simply Blue Staining 
For high amount of BSA, after electrophoresis, the gels were stained 
in Simply Blue solution (Invitrogen) by microwave method according to the 
manufacturer’s instructions. The gel was then distained by MilliQ water until 
the background of the gel was no longer bluish. 
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2.2.5 In-gel Empore Disk Extraction 
              Gel bands were directly excised from the gel and cut into small pieces. 
Gel bands of small amount of BSA which cannot be seen by eyes were cut 
according to their molecular weight. After destaining, washing by water 
followed by 100% ACN to dehydration, gel bands were completely dried to 
“glass” state by freeze drier. The dried gels were broken into powder by a 
homogenizer and then reduced by 10mM DTT at 60°C  for 1h and alkylated 
by 55mM IAA at room tempeture in dark for 1h. The gels were then washed 
by 100mM ABB and 100% ACN and dehydrated in a Speed-Vac. 15μl of 
Trypsin (Promega) was employed to digest BSA at the ratio of 1:50 
(Trypsin:BSA) overnight (12-16h) at 37°C. After digestion, the reaction was 
terminated by adding TFA to a final concentration of 0.1%.  Small pieces of 
Empore Disk were first wet by 100% ACN and equilibrated by 100% 
methanol and then put inside the gel bands solution. The extraction procedure 
was the same as in solution Empore Disk extraction which was described 
above. The eluted peptides were mixed with same amount of matrix solution 
containing 10 mg/ml of α-cyano-4-hydroxycinnamic acid (CHCA) in 
0.1%TFA/50%ACN, and spotted onto a 384-well stainless-steel MALDI 
target plate (Applied Biosystems). 
 
2.2.6 MALDI TOF/TOF MS/MS Analyses 
An ABI 4800 Proteomics Analyzer MALDI TOF/TOF mass 
16 
spectrometer (Applied Biosystems) was used to analyze the samples on the 
MALDI target plates. For MS analyses, typically 1800 shots were 
accumulated for each sample. MS/MS analyses were performed using post-
source decay (PSD) fragmentation.  
 
2.2.7 Data Analysis 
MASCOT search engine (version 2.0; Matrix Science) was used to 
search all of the tandem mass spectra. GPS Explorer™ software version 3.6 
(Applied Biosystems) was used to search files with the MASCOT search 
engine for peptide and protein identifications. Swissprot database was used for 
the search. The MS and MS/MS spectra were combined for the search. 
Cysteine carbamidomethylation and methionine oxidation were selected as 
variable modifications. Three missing cleavages were allowed. Precursor error 
tolerance was set to <0.3 Da and MS/MS fragment error tolerance < 0.3 Da.  
 
2.3 Results 
2.3.1 In Solution Empore Disk Extraction 
              Samples with different amount of commercial digested BSA peptides 
were prepared in 10μl 100mM ABB/0.1% TFA. The samples were 
concentrated by Speedvac to about 1 μl and mixed (1:1) with matrix in 50% 
acetonitrile/0.1%TFA. All the samples were spotted on a stainless steel 
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MALDI plate. But only one or two spots gave signals. Most of the spots did 
not produce any precursor ions suggesting that salt will greatly suppress the 
ionization of peptides. No ion precursors then can be analyzed by MS/MS. 
Thus, desalting is an important step before samples being submitted to 
MALDI-TOF/TOF. 
              Same samples were desalted by cut-off Empore Disk as described 
above. After mixing with matrix solution, the final eluates were spotted to 
MALDI plate to be analyzed by mass spectrometer. The obtained peak lists 
were used for Mascot’s mass fingerprint search combined with MS/MS data 
search. BSA in all samples were detected by MS with reasonable Mascot 
scores (Table 2.1). Down to 10 femtomol BSA can be detected. We also used 
C18 Ziptip to desalt the same samples. Only 1 picomole, 100 femtomol and 50 
femtomol BSA could be detected. The sample with 10 femtomole BSA were 
not detected because of high background noise and low signal intensity.  
              The amount of ACN in elution buffer was optimized. We tried 50% 
ACN, 70% ACN, 90% ACN and 100% ACN. By comparing the signal 
intensity, the Mascot scores and sequence coverage, 90% ACN/0.1%TFA was 
found to be the best elution buffer.  
 
2.3.2 In Gel Empore Disk Extraction 
              Large amount of BSA from 100 picomole down to 1 picomole were 
loaded and run by SDS-PAGE and then stained by Simply Blue. Gel bands 
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were directly excised from the gel and cut into small pieces. The gel was 
digested and desalted by Empore Disk as described above. All of the bands 
with large amount of BSA could be detected with very high scores. 
              Low amount of BSA from 1 picomole down to 1 femtomole were 
also run by SDS-PAGE and stained by silver staining. Gel bands with less 
than 100 femtomole BSA are too week to be seen by eyes (Figure 2.1). So 
they were cut according to the visible bands with sufficient amount of BSA in 
other lanes of the same gel. The bands were digested and desalted by Empore 
Disk. The bands with one picomole and 500 femtomole of BSA are 
consistently detected by MALDI-TOF/TOF every time. However, the 
detectabilities of samples with less than 500 femtomole of BSA are varies 
from experiment to experiment. Sometimes, 10 femtomole BSA loaded on gel 
can be detected with good score! 
              We also compared with normal in gel digestion protocol desalting by 
C18 Ziptip. The difference lies in the procedure after digestion. Normal 
protocol sequesters trypsin and extracts peptide by adding 50% ACN/5% 
formic acid.  Then the solution with extracted peptides was desalted by Ziptip. 
But only band with 1 picomole BSA can be detected. 
 
2.4 Discussion 
              The quality of MALDI mass spectra is highly dependent on the 
sample preparation step prior to MS analysis, especially for in gel sample  
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Table 2.1 MS analysis of in solution and in gel digestion 
 









MS cluster area 
matched 
1 picomole 20 716 36 54.156 
100 femtomole 23 534 44 40.268 
50 femtomole 22 378 40 30.966 
10 femtomole 17 145 30 14.486 
     









MS cluster area 
matched 
1 picomole 41 553 69 36.973 






   1p    500f     100f    50f     10f     5f    1f 
 
 
Figure 2.1 Silver staining of different amount of BSA  
1 picomol, 500 femtomol, 100 femtomol, 50 femtomol, 10 femtomol, 5 
femtomol to 1 femtomol BSA (From left to right)were loaded and run by 









preparation. In gel digestion is much trickier than in solution digestion. The 
peptides may crosslink with gel matrix and hard to be extracted from it. The 
recovery of peptides sometimes is quite low which makes it hard to be 
detected by mass spectrometer. Different staining methods also affect the 
efficiency of in gel digestion. Silver staining is not as compatible as Simply 
Blue or Commassie blue staining with MS. The formaldehyde in most of 
silver staining reagents is possible to crosslink proteins to gel matrix and 
reduce the ratio of peptides from diffusing to solution. Our method is not only 
efficient in in-solution digestion, but also may improve the low recovery of in-
gel digestion. After proteins in gel are digested by trypsin, some of peptides 
will diffuse from the gel into solution. We hypothesize that a equilibrium of 
peptide distribution between gel and solution was established. When Empore 
Disk was put into the solution, peptides in solution were concentrated to it so 
that the concentration of free peptides in solution were decreased. To keep the 
equilibrium, more peptides in gel were diffused out to solution. The binding of 
peptides to Empore Disk shift the equilibrium. As a result, peptides were 
gradually migrated from gel to Empore Disk.  
              Empore Disk has high capacity. For low amount of peptides, only 
small piece is needed. The small material allows small volume of elution 
buffer which makes the avoidance of Speedvac possible.  Speedvac dry down 
and recovery were reported to lead to adsorptive losses (Stewart et al., 2001). 
Minimizing losses is very important especially for low amount of proteins. 
Losses can occur during every step: being extracted from gel, binding to 
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membrane, elution from the membrane, Speedvac dry down and recovery. It 
can also occur due to binding to the plastics the samples are contained in, such 
as tubes, tips etc. Trying to avoid or reduce the losses in every step became the 
key element for low amount samples. The use of Empore Disk can reduce 
many of the losses as explained above. We also used low-binding tubes to 
further prevent the losses of binding to plastics. 
              Our result showed that Empore Disk extraction can detect proteins 
down to 10 femtomole in in-solution digestion and at least 500 femtomole in 
in-gel digestion. Interestingly, very low amount of peptide can be detected 
sometimes. We got good signals from the samples with 1 femtomole BSA or 5 
femtomole BSA in in-gel digestion while nothing can be detected in the 
samples with 50 femtomole and 100 femtomole. Such situation happened 
several times. One possible reason we can provide is that the mixing of 
peptides and matrix solution and distribution of the mixture on MALDI spots 
are not equal. The peptides in low amount samples are few. When beam of 
Laser fires on the spot, it’s random. Only part of the matrix-sample mixture 
will be induced into ions. If the beam happens to fire the area where is full of 
peptides, it will get strong signals.   
              Compared to desalting with Ziptip, the efficiency of Empore Disk 
was slightly better. Considering their cheap material costs and easy handling 




              We have presented a new method for desalting and extraction of 
peptides from in-solution an in-gel digestion. It is not only suitable for sample 
preparation prior to MALDI-MS, but also LC/MS analysis. The Empore Disk 
extraction minimizes the losses of samples and offers a very effective and 
convenient tool for sample preparation. The procedure is simple, reproducible 
and economical. Its handling is easy and convenient for batch samples. These 
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3.1.1 Mass Spectrometry (MS) 
In the post-genome era, mass spectrometry (MS) has emerged as a 
powerful tool to quickly and efficiently identify proteins in biological samples, 
placing MS at the forefront of technologies in proteomics research. MS is a 
highly sensitive tool capable of analyzing samples ranging in size from small 
molecules to whole viruses. 
During the last decade, great advances in MS instrumentation and 
techniques revolutionized protein chemistry and fundamentally make it 
possible to investigate the proteome of a cell, an organ or even an organism. 
How to generate ions from large, nonvolatile analytes such as proteins and 
peptides without significant analyte fragmentation is the major problem when 
applying mass spectrometry to biological research. This difficult problem is 
solved by two technical breakthroughs in the late 1980s: the development of 
the two soft ionization methods - electrospray ionization (ESI) and matrix-
assisted laser desorption/ionization (MALDI) (Karas and Hillenkamp, 1988; 
Fenn et al., 1989; Hillenkamp and Karas, 1990) which catalysed the quick 
development of MS instruments later. Now, commercial MS instruments can 
offer routine picomole to attomole analytical sensitivity of a large variety of 
compounds, including: proteins, peptides, carbohydrates, oligonucleotides, 
natural products, drugs and drug metabolites. Perhaps most exciting is that the 
developmental stage of mass spectrometry has not stopped; innovations such 
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as nanoelectrospray, curved reflectrons and electrospray with orthogonal 
spraying continue to expand its capability. 
The five basic parts of any mass spectrometer are: a vacuum system; 
a sample introduction device; an ionization source; a mass analyzer; and an 
ion detector. Combining these parts, a mass spectrometer determines the 
molecular weight of molecules by ionizing, separating, and measuring 
molecular ions according to their mass-to-charge ratio (m/z). First, an 
ionization source ionizes the molecule of interest, then a mass analyzer 
differentiates the ions according to their mass-to-charge ratio and finally, a 
detector measures the ion beam current. Each of these elements exists in many 
forms and is combined to produce a wide variety of mass spectrometers with 
specialized characteristics. 
Both Electrospray ionization (ESI) and Matrix-assisted laser 
desorption ionization (MALDI) mass spectrometry are sensitive ionization 
sources for mass measurement and can provide surprisingly large amount of 
other information as well. The ability to analyze complex mixtures has made 
ESI and MALDI very useful for the examination of proteolytic digests, an 
application otherwise known as peptide mass fingerprinting (PMF). Through 
the application of sequence specific proteases, mass analysis is performed on 
the resulting proteolytic fragments thus yields mass information of the 
fragments.  The specific protease fragmentation pattern is then compared with 
the patterns predicted for all proteins within a database and matches are 
statistically evaluated. 
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Electrospray ionization (ESI) is one of the most exciting ionization 
techniques for biomolecules. It generates ions directly from solution (usually 
an aqueous or aqueous/organic solvent system) by creating a fine spray of 
highly charged droplets in the presence of a strong electric field.  As the 
droplets pass through a heated chamber, the buffer is evaporated, sending 
desolvated peptide ions to the mass analyzer. As the peptide ions enter the 
mass analyzer, their mass/charge ratios are measured in real time and spectrum 
is generated.  Since ESI generates ions directly from solution, it is especially 
useful for the shotgun analysis which refers to strategies that involve the 
proteolytic digestion of a mixture of proteins and the subsequent analysis of 
the resulting even more complex mixture of peptides (McCormack et al., 
1997). This shotgun technique usually detects more low abundant proteins in a 
medium complex sample than the gel-MS approach. Thus we have adapted 
mainly this shotgun proteomics approach to character the pulled-down Ku70 
protein complex. 
Matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS), first introduced in 1988 by Tanaka and independently by 
Hillenkamp and Karas, has become a widespread analytical tool for peptides, 
proteins and most other biomolecules. MALDI provides for the nondestructive 
vaporization and ionization of both large and small biomolecules. In MALDI 
analysis, the analyte is first co-crystallized with a large molar excess of a 
matrix compound, usually a UV-absorbing weak organic acid, after which 
pulse UV laser radiation of this analyte-matrix mixture results in the 
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vaporization of the matrix which carries the analyte with it. The matrix 
therefore plays a key role by strongly absorbing the laser light energy and 
causing, indirectly, the vaporization and ionization of the analyte. The matrix 
also serves as a proton donor and receptor, acting to ionize the analyte in both 
positive and negative ionization modes, respectively. 
To obtain more structural information on the molecular ions generated 
in the electrospray ionization and MALDI ionization sources, it has been 
necessary to apply tandem mass spectrometry (MS/MS) to induce 
fragmentation. Fragmentation of precursor ions is accomplished either through 
application of 'slow heating' methods or of more recently developed gas-phase 
ion-ion reactions or ion-electron reactions (Horn et al., 2000; Shukla and 
Futrell, 2000; Zubarev et al., 2000; Sleno and Volmer, 2004). The most 
commonly used slow heating fragmentation method is low-energy CID (also 
known as collisionally activated or aided dissociation, or CAD). It involves 
slow transfer of energy by collision with a neutral molecule to the precursor 
ions such that the internal energy of the ions exceeds the energy needed for 
fragmentation. Collision-induced dissociation is accomplished by selecting an 
ion of interest with a mass analyzer and introducing that ion into a collision 
cell. The selected ion then collides with a collision gas (typically argon, 
helium or nitrogen) leading to the disruption of peptide bonds. The fragments 
are then analyzed to obtain a fragment ion spectrum, which is rich in sequence 
information. Finally, protein database search engine (such as SEQUEST, 
Mascot, etc.) compares the acquired MS/MS spectrum to theoretical spectra 
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generated from protein sequences in an appropriate database and identifies the 
proteins in the original samples. 
Immediately following ionization, gas phase ions enter a region of the 
mass spectrometer known as the mass analyzer. The mass analyzer is used to 
separate ions within a selected range of mass-to-charge (m/z) ratios. The 
analyzer is an important part of the instrument because of the role it plays in 
the instrument's accuracy and mass range. Ions are typically separated by 
magnetic fields, electric fields, or by measuring the time it takes an ion to 
travel a fixed distance. Recently, the most commonly used mass analyzers 
include quadrupole, ion trap, time-of-flight (TOF) mass analyzers. Coupled to 
ESI and MALDI, they provide surprisingly sensitive and accurate result 
(Aebersold and Goodlett, 2001). 
State-of-the-art proteomic workflow involves multiple interdependent 
steps: sample preparation, protein-peptide separation, mass spectrometry and 
data analysis. Improvements in any of these steps can increase the accuracy 
and sensitivity of analysis. In order to reduce the complexity of the samples, 
the proteins or proteolytic peptides are usually separated before submitted to 
mass spectrometry. Both one-dimensional sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (SDS-PAGE) and, providing even greater 
separative capacity, two-dimensional gel electrophoresis (2D-PAGE) are 
powerful tools for the separation and analysis of proteins. One common 
workflow in proteomics involves 1D-PAGE or 2D-PAGE followed by mass 
spectrometry-based identification.  For interface with electrospray ionization 
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(ESI), some of the most popular and effective separation techniques use high-
performance liquid chromatography (HPLC), a liquid interface allows for 
coupling the separation step directly to the ionization source of the mass 
spectrometer. Reverse-phase (RP) chromatography is the most commonly 
used technique for separating peptides. For the most complex mixtures of 
proteins or peptides, it is necessary to add another dimension of separation. 
This is most commonly accomplished using a strong-cation-exchange (SCX) 
column for the first dimension, followed by multiple RP separations. Other 
separation strategies that have been utilized in proteomics workflows include 
other types of HPLC, isoelectric focusing, capillary electrophoresis and chip-
based separations (Goodlett and Yi, 2002; Issaq et al., 2002; Shen and Smith, 
2002; Delahunty and Yates, 2005). 
Due to its sensitivity and specificity, mass spectrometry is widely 
applied to identify protein complex in combination with a proper biochemical 
purification of proteins. This strategy is becoming an important tool to define 
relations existing among gene products. 
 
3.1.2 Tandem Affinity Purification Strategy 
The transmission of a wide range of biological signals and the 
proceeding of  all the biological activities depend upon direct physical 
interaction of specific cellular proteins. A more thorough understanding of the 
precise mechanisms of these signal transduction pathways and biological 
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processes relies on the identification and biochemical characterization of the 
specific molecules involved. Protein does not act alone.  Instead, they usually 
interact with one another to exert their cellular function in concert.  The 
resulting protein complexes are highly ordered dynamic structures that 
assemble, store and transduce biological information. 
The availability of complete genome sequence of several organisms 
provides an exceptional opportunity to analyze the different functions 
governed by these genes. Many researchers are looking for high throughput 
technique to systematically study protein-protein interaction networks. This 
would open the way for a chain of predictions: open reading frame function, 
complex formation, and supramolecular organization of the proteome. Large-
scale two-hybrid screening has been used for this purpose (FromontRacine et 
al., 1997; Ito et al., 2000; Uetz et al., 2000). However, the results are often 
false-positive and false-negative, especially when performed in heterologous 
organisms, and restricted to the description of pairs of proteins.  Moreover, the 
limited set of conditions makes it desirable to use additional strategies to 
easily detect protein interactions. 
In characterizing binding partners for a molecule of interest using MS, 
the major challenge is to identify bona fide interacting partners versus sample 
contaminants.  Because of the sensitivity of the mass spectrometry, detection 
and identification of protein by MS is not the bottle neck, while the quality of 
the purification method plays a more and more critical role in the ultimate 
success of an experiment. 
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Classical biochemical purification methods rely heavily on the 
biophysical properties of a given protein. For example, a typical 
immunoprecipitation (IP). However, antibodies usually cross-react with one or 
more irrelevant proteins; Moreover, many proteins bind non-specifically to the 
solid support resin and antibody. A typical IP will therefore contain not only 
cross-reactive and other non-specific contaminating proteins, but will also 
bring down their interacting partners, resulting in the identification of multiple 
proteins that are unrelated to the target complex, thus generate significant 
background. Since each protein is unique, designing a purification protocol for 
a given protein is often empirical. The lack of a generic protein complex 
purification protocol hampers the progress in elucidating the functional 
interactions between cellular proteins. 
Among a plethora of protein purification techniques, affinity 
purification through epitope-tag appears to be the most efficient and gentle 
discriminatory separation technique for the retrieval of protein complexes. 
Well-characterized small epitope-tags such as Flag, 6XHis or GST have been 
widely used in affinity purification of recombinant proteins or protein 
complexes. However, nonspecific binding is the biggest problem for these 
single-step purification. How to reduce nonspecific contaminaton becomes the 
key for the purification of protein complexes. Two generic affinity purification 
procedures utilizing two consecutive affinity purification steps have been 
developed and proven to be highly effective in the identification of protein 
complexes in yeast (Rigaut et al., 1999; Puig et al., 2001) with minimal 
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background. Rigaut et al. described the tandem affinity purification (TAP) 
method (Rigaut et al., 1999). They chose IgG-binding units of protein A of 
Staphylococcus aureus (ProtA) and calmodulin-binding peptide (CBP) as the 
two tags among several widely used tags, eg. FLAG tag, the Strep tag, the His 
tag, the chitin-binding domain (CBD) etc. by selecting the yeast SmX4p 
protein. 
In this method, the protein of interest must be fused to the TAP tag and 
expressed in the organism or cell line under investigation. The TAP tag 
contains two epitope tags:  a ProtA tag and a CBP tag. Both epitope types are 
separated by spacer regions and a cleavage site for tobacco etch virus (TEV) 
protease. Extracts prepared from cells expressing the TAP-tagged protein are 
subjected to two successive purification steps. The first purification step 
involved binding of the ProtA tag to an IgG column and eluting bound 
materials by incubation with TEV protease. This elution method significantly 
reduced the contaminating proteins bound nonspecifically to the column. The 
eluates which contained protein complexes were further purified by incubation 
with calmodulin coated beads to remove TEV protease and contaminants. 
Highly purified protein complexes were eluted by adjusting concentration of 
calcium ions with EGTA. 
Compared to the conventional chromatographic methods, TAP 
method has great advantages. It is efficient, yielding pure protein complex in 
sufficient amounts for mass spectrometric (MS) identification from small 
sample size. It can produce an extremely pure preparation of the protein of 
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interest with associated proteins. The two specific elutions prevent most of  
contaminants. Furthermore, the whole procedure including the final elution 
step can be carried out under mild, nondenaturing conditions under which the 
purified protein complex usually retains functionality. 
Although the TAP method has been originally developed in the 
budding yeast Saccharomyces cerevisiae, this approach has been successfully 
applied to other organisms including bacterial (Gully et al., 2003; Kumar et al., 
2004; Butland et al., 2005), mammalian (Westermarck et al., 2002; Knuesel et 
al., 2003; Bouwmeester et al., 2004; Brajenovic et al., 2004) , Drosophila 
(Forler et al., 2003), plant (Rohila et al., 2004) and trypanosomatids 
(Aphasizhev et al., 2003a; Aphasizhev et al., 2003b; Panigrahi et al., 2003). 
Other tandem-affinity tags include a modified version of the TAP-tag 
in which the CBP part is replaced by the S-tag (Cheeseman et al., 2001) and 
combinations of multi-histidine-tags with FLAG (Denison et al., 2005; 
Hannich et al., 2005; Kim, S. C. et al., 2006), myc-tags (Graumann et al., 2004) 
or bio-tag (Tagwerker et al., 2006) have also been developed. A similar 
technique using three different tags (CBP, 6XHis, HA) called MAFT for 
“multiple affinity purification” has also been developed and used for 




In this project, we have applied epitope-tag purification and mass 
spectrometry to isolate and identify Ku70 protein complex to elucidate the 
roles of Ku70 in biological processes. 
Ku70 is a protein with multiple functions. It was originally 
recognized as an autoantigen as one component of the Ku antigen by 
autoantibodies from certain Japanese patients with scleroderma-polymyositis 
overlap syndrom (Mimori et al., 1986) and was subsequently found to be an 
autoantigen in patients with several other autoimmune diseases, including 
systemic lupus erythematosis, Graves disease, and Sjogren syndrome (Reeves, 
1992). Ku antigen is a complex composed of two subunits of 70 and 80 kDa 
which are designated Ku70 and Ku80, respectively (Mimori et al., 1986). The 
Ku70 and Ku80 genes are distributed in a wide variety of eukaryotic species, 
ranging from yeast to human (Dynan and Yoo, 1998). 
Ku70 is essential for the repair of DNA double-strand breaks (DSB), 
which can be induced directly by a variety of damaging agents, or indirectly as 
a result of endogenous damage arising from the cell’s own metabolism by 
nonhomologous end joining (NHEJ) and the rearrangement of antibody and T 
cell receptor genes via V(D)J recombination which is a physiologic DNA 
double strand breakage and rejoining process restricted to lymphoid cells 
(Rathmell and Chu, 1994; Featherstone and Jackson, 1999).  In this role, Ku70 
complexes with Ku80 to form the DNA-binding component of the DNA-
dependent serine/threonine protein kinase (DNA-PK) (Leesmiller et al., 1990; 
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Anderson, 1993; Gottlieb and Jackson, 1993; Weaver et al., 1995). The crystal 
structure of Ku bound to DNA was reported to show the mechanism of Ku-
end recognition (Walker et al., 2001) and the three-dimensional structure of 
the human DNA-PKcs/Ku70/Ku80 complex was also reported (Spagnolo et al., 
2006). Ku protein is also important in activating DNA-PK (Jin and Weaver, 
1997). 
The Ku70/80 heterodimer also has important roles in telomere 
maintenance and transcriptional regulation (Tuteja, R. and Tuteja, 2000). Ku 
might function as part of a telomeric length sensing system protecting 
chromosomal termini from nucleolytic attack, as was shown in yeast (Boulton 
and Jackson, 1996) and mammals (Bailey et al., 1999; Bianchi and de Lange, 
1999; Hsu et al., 1999; Samper et al., 2000).  Ku70 and Ku80 heterodimer can 
also bind to telomeric sequence independent of the DNA-PKcs (Hsu et al., 
2000) to prevent chromosomes end-to-end fusions. 
Although Ku protein and DNA-PKcs always function together, several 
studies showed that Ku protein may play some role independent of DNA-PK 
activity. As expected, Ku protein knockout mice have a deficiency in DNA 
DSB repair, but in addition, they show a retardation in growth (Nussenzweig 
et al., 1996; Gu, Y. S. et al., 1997). However, the retardation in growth was 
not shown in DNA-PKcs-knockout mice (Gao et al., 1998). These knockout 
experiments suggest that there is an important link between growth control 
and Ku protein. 
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Although Ku70 always forms a heterodimer with Ku80 and involves 
biological process together, it may have its own functions that are independent 
of Ku80. There are some differences in the phenotype between Ku70- and 
Ku80-knockout mice (Nussenzweig et al., 1996; Zhu, C. M. et al., 1996; Gu, 
Y. S. et al., 1997; Li et al., 1998). For example, Ku70-knockout mice have 
small populations of mature T lymphocytes and a significant incidence of 
thymic lymphoma, but Ku80-knockout mice do not. Ku70 has been reported 
to show Ku80-dependent and -independent DNA binding, whereas Ku80 
requires association with Ku70 for DNA binding (Wang, J. S. et al., 1998). 
Altered expression of  Ku70 was found in many tumors, eg. oral cavity 
carcinomas(Korabiowska et al., 2006b), colorectal carcinoma (Komuro et al., 
2005; Korabiowska et al., 2006a), nasopharyngeal carcinoma (Lee et al., 2005) 
etc., suggesting that Ku70 may involve in the tumorigenesis and may become 
the target for anti-tumor drugs. 
Recent studies suggest that Ku70 has a Bax inhibitory activity that is 
independent of previously recognized DNA damage repair function. 
Consistent with this hypothesis, it was reported that Ku70_/_ knockout mice 
are hypersensitive to ionizing radiation (Ouyang et al., 1997) and have 
increased apoptotic neuronal death during embryonic development (Gu, Y. S. 
et al., 2000). Fibroblasts derived from Ku70-deficient mice become 
hypersensitive to several anti-cancer drugs that do not induce DNA damage 
(Kim, S. H. et al., 1999). Chechlacz  et al. also reported that cells from Ku70 
knockout mice are hypersensitive to agents, such as staurosporine (STS), that 
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promote apoptosis in the absence of DNA damage (Chechlacz et al., 2001).  
Furthermore, ectopic expression of Ku70 protects human colon cancer cells 
(SW480) against curcumin-induced apoptosis (Rashmi et al., 2004). 
Ku70 was originally reported to be a nuclear protein, consistent with 
its functions as a DNA repair protein. However, several studies have revealed 
the cytoplasmic or cell surface localization of Ku proteins in various cell types 
(Prabhakar et al., 1990; Dalziel et al., 1992; Grawunder et al., 1996). Manabu 
Koike et al. found that Ku70 is in the nuclei in interphase cells. But in mitotic 
cells, most of Ku70 were found diffused in the cytoplasm (Koike et al., 1999). 
It is suspected that the less abundant cytoplasmic pool is responsible for the 
sequestration of Bax, the protein that will induce mitochondrial-dependent cell 
death signals in mammalian cells (Sawada et al., 2003a). By screening a 
human cDNA library to identify inhibitors of Bax, Sawada et al. (Sawada et 
al., 2003b) identified the Bax-binding and Bax inhibiting properties of Ku70. 
More recent work has shown that Ku70 is also an acetylation-sensitive binding 
partner for Bax (Cohen et al., 2004). They showed that Ku70 binds to Bax 
through its C terminus. Five lysine residues within this domain (539, 542, 544, 
553, and 556) can be acetylated by CBP and PCAF. They suggested that 
acetylation of  C terminal of Ku70 will regulate the Bax-mediated apoptosis. 
The similar result was demonstrated in NB cells (Subramanian et al., 2005). 
Besides the two antiapoptotic effects-facilitating DSBR and 
sequestering Bax to prevent its translocation to mitochondria, the most recent 
research showed that Ku70 also has other antiapoptotic functions in GzmA-
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induced cell death, which are blocked when GzmA proteolyses Ku70 (Zhu, P. 
C. et al., 2006). 
Given Ku70’s dual role in DNA end joining and suppressing apoptosis, 
it could conceivably be a central player in coordinating DNA repair with the 
decision between cell survival and programmed cell death. In this project, we 
will probe in-depth to the Ku70 protein complex to decipher the role of Ku70 
in regulating DNA repair and apoptosis. 
 
3.2 Materials and Methods 
3.2.1 Plasmid Constructions 
The Ku70 cDNA was amplified using the following oligonucleotides 
as primers for the PCR: forward primer 5’CTGGATCCGATGTCAGGGTGG 
GAGTC3’ and reverse primer 5’GATCGCTCACGCGGCCGCTCAGTCCTG 
GAAGTGCT3’ which introduce a BamHI cutting site into the 5’ terminal of 
Ku70 cDNA and a NotI cutting site into the 3’terminal of Ku70 cDNA. PCR 
product was purified from the gel (QIAquick Gel Extraction Kit, Qiagen, 
Germany) and double digest by BamHI and NotI. The digested PCR product 
was purified (QIAquick PCR Purification Kit, Qiagen, Germany) and cloned 
into the BamHI and NotI sites of pcDNA3-NTAP vector (provided by Institute 
for Systems Biology) to generate pcDNA3-NTAP-Ku70. The plasmid 




3.2.2 Preparation of Ku70 Mutants 
Ku70 site-specific mutants were formed by incorporating mutant 
oligonucleotides by strand extension reactions. The QuikChange® Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used according to the 
manufacturer’s recommendation. Each mutant was identified by DNA 
sequencing. The primer set employed were as follows: Ku70-L385R: forward 
primer 5’ GCTCAACCCTGTTCAGTGCTAGGCTCATCAAGTGTCTGG 3’, 
reverse primer 5’ CCAGACACTTGATGAGCCTAGCACTGAACAGGGTT 
GAGC 3’, Ku70-K553A: forward primer 5’ CGATAATGAAGGTTCTGGA 
AGCGCAAGGCCCAAGGTGGAG 3’, reverse primer 5’ CTCCACCTTGG 
GCCTTGCGCTTCCAGAACCTTCATTATCG 3’, Ku70-E548A: forward 
primer 5’ CCAAGAGAAAACACGATAATGCAGGTTCTGGAAGCAAAA 
GGCC 3’, reverse primer 5’ GGCCTTTTGCTTCCAGAACCTGCATTATCG 
TGTTTTCTCTTGG 3’. 
 
3.2.3 Cell Culture 
FreeStyle 293-F Cells were bought from Invitrogen.  Cells were 
cultured in FreeStyle 293 Expression Medium in sterile Erlenmeyer flask and 
maintained in a 37°C incubator containing a humidified atmosphere of 8% 
CO2 in air on an orbital shaker platform rotating at 150 rpm. HEK293 cells 
were cultured in Minimum Essential Medium (GIBCO) supplemented with 
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10% fetal bovine serum (FBS), 2mM L-glutamine, 1%Non-Essential Amino 
Acid solution (NEAA), 1mM NaPyravate, 100u/ml Penicillin and 100mg/ml 
Streptomycin at 37°C in 5% CO2. 
 
3.2.4 Transient and Stable Protein Expression 
Plasmids were transient transfected into HEK293 cells grown at 90% 
confluency using lipofectamine2000 (Invitrogen) according to the 
manufacturer’s instructions. FreeStyle 293-F cells were transfected at the 
density of  1 x 106 cells/ml using 293fectin (Invitrogen) according to the 
manufacturer’s instructions.  FreeStyle 293-F cells stably expressing TAP 
tagged and FLAG tagged Ku70 were obtained by limiting dilution and the 
selection of 750 μg/ml Geneticin (GIBCO). Correct integration of constructs 
and expression of TAP-tagged and FLAG-tagged proteins were verified by 
immunoblotting with normal mouse or rabbit IgG antibodies and Flag 
antibody (Sigma). 
  
3.2.5 Cell lysis and Quantitative Protein Essay for Cell Lysate 
HEK293 cells were harvested when they were at 90% confluency via 
trypsinization, centrifugation, and washed in phosphate-buffered saline twice. 
FreeStyle 293-F Cells were harvested when they reached the density of 3 x 106 
cells/ml and then centrifuged and washed in PBS twice. Cells were then lysed 
in lysis buffer ((20% glycerol, 420 mM NaCl, 20 mM HEPES pH 7.9, 0.5% 
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igepal CA-630 (Sigma ), 0.2 mM EDTA, 0.5 mM DDT, 0.5 mM PMSF) 
containing protease inhibitors cocktail (Sigma). After 1h incubation on ice, the 
lysates were centrifuged for 30 min at 13,000rpm. 
The amount of protein dissolved in supernatant was determined by 
employing the method of Bradford. 10μl of the proteins and a series of BSA 
(Sigma) solutions with the concentration of 500μg/ml, 250μg/ml, 125μg/ml, 
62.5μg/ml, 31.25μg/ml, prepared in PBS, were added into 200μl diluted 
Bradford protein assay reagent (Bio-Rad Laboratories, California, USA) 
which was made by mixing Milli-Q water and Bradford protein assay reagent 
in the ratio of 4:1. 
The absorbance of the preparations was determined at 595nm using a 
ninety-six-well microtiter plate (Greiner, USA) with a spectrophotometer. 
With the absorbance reading of the BSA solutions as standards, standard curve 
was plotted. From the standard curve, the concentrations of proteins present in 
the samples were determined. 
 
3.2.6 SDS-polyacrylamide Gel Eletrophoresis (SDS-PAGE) 
The prepared samples were analyzed on different concentrations of 
SDS-polyacrylamide gels according to the proteins which were focused with a 
Mini protein II electrophoresis apparatus (Bio-Rad Laboratories, California, 
USA) or on 4-12% (w/v) gradient pre-cast NuPAGE® Novex Bis-Tris gels 
(Invitrogen) with a XCell SureLock™ Mini-Cell (Invitrogen).        . 
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3.2.7 Immunoprecipitation and Western Blot 
Protein G Sepharose beads (Amersham) were washed by 10mM Tris-
HCl and blocked by 600μg/ml BSA first in IP buffer (PBS+0.1%Triton X). 
Clear cell lysate containing 500 μg of total protein were precleared by 
incubating with 30 μl of protein G-Sepharose beads for 1h at 4 °C. After 
removal of the beads, the extracts were incubated overnight (~14 h) at 4 °C 
with 2 μg anti-GFP antibody (Santa Cruz) or monoclonal anti-Ku70 antibody 
(Santa Cruz). 30μl protein G Sepharose beads were then added into the 
extracts and incubated for 3h. The beads were collected by centrifugation at 
2000rpm for 5min at 4 °C and washed three times with 1ml of IP buffer. 
For Western blot analyses, the beads were resuspended in 30 μl of 2× 
SDS-polyacrylamide gel sample buffer, boiled for 5mins, and proteins were 
resolved by SDS-PAGE. Proteins were then transferred onto PVDF 
membranes, blocked with 5% skim milk in TBST (25 mM Tris, pH 7.4, 137 
mM NaCl, 2.7 mM KCl, 0.1% Tween20) for 1h at room temperature, and then 
incubated for 1 h at room temperature or overnight at 4 °C with the 
appropriate antibody in 2.5% skim milk. After 1 h of incubation at room 
temperature with the appropriate secondary antibodies, the blots were 
developed using ECL reagents (Amersham Biosciences). 
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3.2.8 Purification of Flag-tagged Ku70 
              Appropriate amount of the ANTI-FLAG M2 affinity gel was washed 
twice with 1 ml cell lysis buffer. The clear cell lysate containing 1-10mg total 
protein was diluted 2 times by 20mM HEPE and then added to the washed 
beads. After incubation with gentle rotation at 4°C overnight, the affinity gel 
was transferred to a clean Bio-spin column (Bio-Rad) and then washed by 20 
column volumes of TBS. Ku70 was eluted by 3X FLAG elution solution (100 
ng/μl 3X FLAG peptide in TBS). 
 
3.2.9 TAP Tag Purification 
Appropriate amount of IgG sepharose 6 fast flow (Amersham) were 
washed 3 times with lysis buffer. The clear cell lysate containing 5-20mg total 
protein was diluted 5 times by 20mM HEPES until the concentration of igepal 
CA-630 to 0.1% and then added to the washed beads. After incubation with 
gentle rotation at 4°C for 4 hours, the IgG beads were washed 3 times with 
1ml diluted lysis buffer and 3 times with TEV buffer (10mM HEPES-KOH 
pH8.0, 150mM NaCl, 0.1% igepal CA-630, 0.5mM EDTA, 1mM DTT). The 
IgG beads were then resuspended in 300μl TEV buffer containing 150 units 
TEV protease (Invitrogen) and incubated overnight at 4°C. The IgG beads was 
spined down and the supernatant was transferred to a fresh tube. The post-
cleavage IgG beads were then washed 3 times by 300μl calmodulin binding 
buffer (10mM ß-mercaptoethanol, 10mM HEPES-KOH pH8.0, 150mM NaCl, 
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0.1% igepal CA-630, 1mM MgOAc, 1mM imidazole, 1mM CaCl2). All the 
washed supernatants were combined with post-cleavage supernatant and 
transferred to the tube containing the calmodulin-sepharose 4B (Amersham) 
which was washed 3 times by 1ml calmodulin binding buffer and incubate 120 
minutes with gentle agitation at 4°C. The Calmodulin beads were then 
transferred to a clean Bio-spin column (Bio-Rad) and washed 3 times with 10-
20 volumes calmodulin binding buffer followed by 2 times with 10-20 
volumes calmodulin rinsing buffer (50mM ABB pH 8.0, 75mM NaCl, 1mM 
MgOAc, 1mM imidazole, 2mM CaCl2). Two volumes of calmodulin elution 
buffer (50mM ABB pH 8.0, 25mM EGTA) was added into the column and 




Three crosslinkers EDC, DMP, formaldehyde were used to crosslink 
the protein complex during TAP tag purification before or after the protein 
complex was cleaved with tobacco etch virus protease (TEV) from IgG beads. 
Formaldehyde was added at the concentration of 0.1% and incubated at 4°C 
for 5 min with slow mixing. The reaction was quenched with 125 mM glycine, 
pH 7.0.  Fresh prepared 6.54mM EDC in crosslink buffer (20 mM MES–
NaOH pH 6.0, 100 mM NaCl, 2 mM MgCl2, 0.5 mM EDTA pH 8.0, 10% 
glycerol) was added to the beads to crosslink the protein complex and reacted 
45 
for 1 hours at 4°C. 2-mercaptoethanol (final concentration of 20 mM) was 
added to quench the reaction.  DMP was dissolved in TEV buffer at the final 
concentration of 5.78mM and added to the bead to crosslink the protein 
complex. After 1h incubation at 4°C, the reaction was stopped by adding Tris 
or glycine at a 20-50 mM final concentration. 
 
3.2.11 Silver Staining 
After electrophoresis, the gels were fixed in fixing buffer (40% 
Ethanol, 10% Acetic acid, 50% H2O) and stained using SilverQuest Silver 
Staining Kit (Invitrogen) according to the manufacturer’s instructions. 
 
3.2.12 Cell Cycle Analysis 
Cells were synchronized to M phase by being treated with 40ng/ml 
nocodazole for 12h and then trypsinized and replanted to release cells from 
nocodazole (0h). The cells were then observed under confocal microscope at 
different time points and collected for flow cytometry analysis. 
 
3.2.13 Propidium Iodide Staining of Cells for FACS Analysis 
Cell pellet was washed with PBS supplemented with 1% serum. 
Chilled 80% ethanol was added very slowly to the pellet while vortexing to 
prevent clumbing. Cells were then left in the fixative at 4°C for 24h.  After 
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fixing, cells were spinned down and washed with PBS supplemented with 1% 
serum. Propidium Iodide/ RNaseA solution was added to resuspend cells and 
incubated at 37°C for 30 minutes in dark. Cells are then ready for FACS 
analysis. 
 
3.2.14 MTS Assay 
Cells were seeded at 20,000 cells/well in 96-well plates and treated 
with a varity of HDAC inhibitors in different concentrations for 60h. Cell 
viability was quantitated with an MTS assay as per the manufacturer’s 
instructions (Promega, Madison, Wis). 
 
3.2.15 Sample Preparation for Mass Spectrometry 
3.2.15.1 In Gel Digestion 
3.2.15.1.1 Gel Bands 
The protein complexes recovered from TAP purification were 
fractionated on a 4-12% SDS-PAGE gradient gel and stained by silver staining. 
Gel bands were directly excised from the gel and destained. After wash by 
water followed by 100% ACN, gel bands were reduced by 10mM DTT at 
60°C  for 1h and alkylated by 55mM IAA at room tempeture in dark for 1h. 
The gels were then washed by 100mM ABB and 100% ACN and dehydrated 
in a speed-Vac or Freeze drier. Trypsin (Promega) was employed (100–200 
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ng/digestion in 100mM ABB) to digest the sample overnight (12-16h) at 37°C. 
After digestion, the peptides were extracted from the gel slices by adding  50% 
acetonitrile, 5% formic acid and sonicating for 30 min. This aqueous samples 
were concentrated in a speed-Vac  and desalted using C18 ZipTips (Millipore, 
Billerica, MA) according to the manufacturer’s instruction. 
 
3.2.15.1.2 Gel Section 
The protein complexes recovered from TAP purification were 
fractionated on a 4-12% SDS-PAGE gradient gel. Gels were divided into 
several sections according to the molecular weight across the entire separation 
range of each lane and sliced into small pieces to sample all potential 
interacting proteins without bias with respect to size and relative abundance. 
Cut bands were reduced, alkylated, and digested as described previously, and 
peptides were sequenced by tandem mass spectrometry (LC-MS/MS). 
 
3.2.15.2 Solution Phase Digestion 
The protein complexes recovered from TAP purification were freeze-
dried and redissolved in 50μl MilliQ water. The concentration of the proteins 
was estimate by Bradford method. DTT was added into the solution at the 
final concentration of 10mM and incubate at 60°C  for 1h to reduce the sample.  
IAA was then added to a final concentration of 20mM to alkylate the proteins 
and incubate for another 1h at room tempeture in dark. Trypsin was employed 
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at the amount ratio of 1:50 (trypsin : protein) to digest the sample overnight 
(12-16h) at 37°C. After digestion, 0.1% TFA was added to terminate the 
reaction. Peptides were sequenced by tandem mass spectrometry (LC-MS/MS). 
 
3.2.15.3 Empore Disk Extraction 
Described in chapter 2 
 
3.2.16 Mass Spectrometry Analysis 
Tryptic peptides were analyzed with a Finnigan Surveyor HPLC 
system coupled online to a LTQ ion trap mass spectrometer (Thermo Electron, 
San Jose, CA) equipped with nano-ESI source. A C18 nanocolumn (i.d. 75 μm, 
length 100 mm, tip 15 μm, New Objectives, Woburn, MA) was packed with 
Magic C18 particles (particle size 5 μm, pore size 150 Å, Michrom 
BioResources, Auburn, CA). The flow rate through the column was 200 
nL/min. A water-acetonitrile gradient was employed with both mobile phases 
containing 0.1% formic acid. The gradient used was 5%-50% acetonitrile over 
60 min. The injection volume was 100 μL. The electrospray mass spectra were 
acquired at a voltage of 1.8 kV, ion transfer tube temperature of 180 °C, 
collision gas pressure of 0.85 mTorr and normalized collision energy of 35% 
for MS2. Ion selection threshold was set to 500 counts for initiating MS2 
while activation q was set to 0.25 and activation time to 30 ms.  The MS scan 
range was  400 - 2000 Da and mass spectra were collected in data-dependent 
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MS2 mode in which five of the highest intensity peaks in each MS scan were 
chosen for CID, with an isolation width of 3 Da. 
 
3.2.17 Data Analysis 
MS/MS data were search with IPI human database by MASCOT 
(Matrix Science, London) database search engine.  Database search was 
performed with carbaminomethylation (Cys) set as fixed modification, 
oxidized methionine (+16 Da) and acetylatioin as viable modifications. Missed 
cleavages of trypsin were set as  two. Peptide charges were confined to 1+, 2+ 
and 3+ and mass tolerance were set to 2.0 Da for peptide precursor ion and 0.8 
Da for fragment ions, respectively. 
 
3.3 Results 
3.3.1 Generation of Stable Mammalian Cell Lines Expressing GFP-tagged, 
FLAG-tagged and TAP-tagged Ku70 
The plasmid pWay20-GFP-Ku70 was kindly provided by Dr. J. 
Donald Capra. For generating stable transfected cell line, lipofectamine2000 
(Invitrogen) was used to transfect the plasmid to HEK293 cell line. Cells were 
selected by 500 μg/ml Geneticin(GIBCO). The selected clones were observed 
under fluorescent microscope to check the cell purity and Ku70 expression 
level. We also constructed the TAP-tagged Ku70 pcDNA3 expression vector 
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and FLAG-tagged pCMV expression vector. The pcDNA3 vector contains a 
Human cytomegalovirus immediate-early (CMV) promoter which allows 
high-level expression in mammalian cells. This plasmid was transfected into 
FreeStyle 293-F cells by using 293 fectin (Invitrogen). FreeStyle 293-F cell 
line is a variant of the 293 cell line that has been adapted to suspension growth 
in FreeStyle 293 expression medium. It can grow in big volume to high 
density which makes it easy and convenient to harvest a large amount of cell 
at one time. It also can be cultured in complementary Minimum Essencial 
Medium (GIBCO) as adherent cells at 37°C in 5% CO2. Normal stable 
transfection methods for suspension cell lines cannot ensure the purity, eg. 
diluting and selecting through several generations by appropriate selective 
medium, or are time consuming, eg. plating single-cell cloning into 96-well 
plates. To prevent the above shortcomings, we transfected 293-F cells in 
suspension status and incubate for 72 h to allow for expression of the 
resistance gene. Then we diluted the cell density and culture them in adhesion 
status with 750 μg/ml Geneticin. The concentration of Geneticin was decided 
by a dose-response test of  Geneticin for 293-F cells. All normal 293-F cells 
were killed under the concentration of 750 μg/ml Geneticin.  After culture for 
several weeks, single colonies were picked and tested by Western blot.  
According to western blot analysis, we found pcDNA3-NTAP-Ku70 vector 
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Figure 3.1. Generation of mammalian stable cell lines 
 
A. Schematic diagram of the structure of recombinant NTAP-tagged Ku70.  
 
B. Schematic diagram of the structure of recombinant GFP-tagged Ku70.  
 
C. Western blot analysis of Ku70 expression using anti-human Ku70 antibody 
(Santa Cruz Biotechnoolgy). Each lane was loaded 30 μg total cell lysates. 
Both NTAP-tagged Ku70 and endogenous Ku70 were detected. 1, control-
293F cells transfected with empoty vector. 2, 293F cells transfected with 
pcDNA3-NTAP-Ku70.  
 
D. Western blot analysis of NTAP-Ku70 expression using Normal mouse IgG 
antibody (Upstate) which can recognize Protein A in TAP tag. Endogenous 
Ku70 can not be recognized by this antibody.  
 
E. Western blot analysis of Ku70 expression using anti-human Ku70 antibody 
(Santa Cruz Biotechnoolgy). Each lane was loaded 50 μg total cell lysates. 
Both GFP-tagged Ku70 and endogenous Ku70 were detected. 1, control-293F 
cells transfected with empoty vector. 2, 293F cells transfected with pWay20-
GFP-Ku70.. 
 
F. Western blot analysis of GFP-Ku70 expression using anti-GFP antibody 
(Santa Cruz Biotechnoolgy). Only GFP-tagged Ku70 was detected. 










3.3.2 Purification of The Ku70 Complex 
Traditional immunoprecipitation (IP) was used to purify Ku70 
complex in our first attempt.  The whole cell lysate was precleared and 
incubated with anti-GFP antibody and then incubated with protein G 
sepharose.  After wash, proteins which still bind to beads were eluted by 
100mM glycine, pH 2.0.  The presence of Ku70 was demonstrated by western 
blot analysis (Figure 3.2, A). But when the eluted proteins were separated by 
SDS-PAGE and silver stained, we could observe a lot of non-specific binding 
proteins.  Even the control lane showed many bands that were from non-
specific binding proteins to the solid support resin or antibody (Figure 3.2, B).  
After we increased the concentration of  NaCl in washing buffer, the 
nonspecific binding still had not been reduced (Figure 3.2, C). The result 
indicated that normal IP is suitable for procedures such as western blotting, 
where the presence of one or more specific proteins is probed and background 
is not revealed. Therefore, a more efficient mass spectrometry compatible 
strategy is needed to purify the Ku70 protein complex. 
In this research, we used TAP tag purification strategy to purify the 
Ku70 complex.  The clear cell lysate were prepared from the stable transfected 
293F cells and incubated with IgG sepharose 6 fast flow. After washing by 
diluted lysis buffer and TEV buffer for 3 times respectively, the IgG beads 
were then incubated with TEV protease overnight at 4°C. The post-cleavage 
supernatant was further incubated with calmodulin-sepharose 4B for 120 
minutes with gentle agitation at 4°C. After washing the beads with 50 volumes 
54 
      A            
        1       2                                                      
                                                   
 
      B                                                                            C  
1         2                                     M               1      2       3      4       5       6 
                                     
 
Figure 3.2 Traditional IP pull down 
 
A. Western blot analysis of IP pull down eluate. IP: anti-GFP. IB: anti-Ku70. 
1, control-293F cells transfected by empty vector. 2, 293F cells transfected by 
pWay20-GFP-Ku70. 
 
B. Silver staining of IP pull down eluate. IP: anti-GFP. 1, control-293F cells 
transfected by empty vector. 2, 293F cells transfected by pWay20-GFP-Ku70. 
 
C. Silver staining of IP pull down eluate. IP: anti-GFP. 1, 3, 5, control-293F 
cells transfected by empty vector, 300mM, 400mM and 500mM NaCl in 
washing buffer respectively. 2, 4, 6, 293F cells transfected by pWay20-GFP-
Ku70, 300mM, 400mM and 500mM NaCl in washing buffer respectively. 
GFP-Ku70
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of calmodulin binding buffer followed by 40 volumes of calmodulin rinsing 
buffer, the proteins bound to the calmodulin beads were eluted by elution 
buffer.  Each step was verified by western blot analysis to monitor the 
presence of Ku70 in the eulate (Figure 3.3, A).  As depicted in Figure 3.3, the 
first step of TAP tag purification with IgG column reduced the complexity of 
the protein mixture.  As a result, Ku70 protein complex was significantly 
enriched.  Second step purification with calmodulin beads further greatly 
reduced the nonspecific proteins compared with the eluate from normal IP pull 
down. The 70 kDa Ku70 was the major protein in the eluates from calmodulin 
beads, suggesting the two-step tandem purification procedure can efficiently 
isolate TAP-Ku70 and its associated proteins from cultured mammalian cells. 
We also used anti-FLAG M2 affinity gel to purify the FLAG-tagged 
Ku70 and the associated proteins. This one step affinity purification was also 
very effective. But the protein profile was a little different from the protein 
profile of TAP-tag purification (Figure 3.3, D). 
 
3.3.3 In Vitro Closslinking of Ku70 Complex 
Although two-step tandem purification greatly reduced the background 
of protein complex, it also would destroy some weak protein-protein 
interactions. Many biologically important interactions between proteins are 
transient or relatively weak. They are possible to be disturbed during the 
purification procedure because of the high dilution of the protein solutions in  
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Figure 3.3 purification of TAP-tagged and FLAG-tagged Ku70 and its 
associated proteins 
 
A. A portion of proteins in each step of purification were separated using 4-
12% SDS-PAGE and verified by western blot. IB: anti-Ku70 
1, Control-293F cells, whole cell lysate 
2, 293F cells transfected by pcDNA3-NTAP-Ku70, whole cell lysate 
3, Cell lysate after incubating with IgG beads 
4, IgG beads after incubating with cell lysate 
5, Post-cleavage supernatant after cleavage with TEV protease 
6, IgG beads after cleavage with TEV protease 
7, Control-IgG beads after cleavage with TEV protease 
8, Post-cleavage supernatant after incubating with Calmodulin beads 
9, Eluate 
10, Control-eluate 
11, Calmodulin beads after elution 
12, Control-Calmodulin beads after elution 
 
B. Silver staining of post-cleavage supernatant (1-step).  
M, Maker. 1, Control. 2, 293F cells transfected by pcDNA3-NTAP-Ku70. 
 
C. Silver staining of TAP tag purification eluate (2-step).  
M, Maker. 1, Control. 2, 293F cells transfected by pcDNA3-NTAP-Ku70. 
 
D. Silver staining of the eluate of FLAG-tagged Ku70. 
M, Maker. 1. Control. 2. 293F cells transfected by pCMV2B-FLAG-Ku70 
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the later steps. Transient and weak protein interactions can be preserved by 
covalently crosslinking protein complexes in vivo prior to purification. But 
crosslinking proteins in the very early stage may increase the chance to pull 
down nonspecific proteins. We therefore crosslinked the protein complex in 
vitro between the two steps of purification to facilitate the identification of 
protein complexes that are formed by less stable or transient interactions and 
reduce the background as many as  possible at the meantime. 
We tested three crosslinkers, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), dimethyl pimelimidate (DMP) and formaldehyde, to 
crosslink the protein complex. Formaldehyde is a widely used crosslinker.  It 
is usually applied to crosslink protein and DNA in chromatin IP.  It crosslinks 
proteins by forming methelene bridges between reactive groups like amido, 
guanidino, thiol, phenol, imidazole and indolyl groups. But it crosslinks 
proteins nonspecifically, it can crosslink protein-protein or protein-DNA 
within a ~20A radius. EDC is a zero-length crosslinking agent used to couple 
carboxyl groups to primary amines. This crosslinker has been used in diverse 
applications such as forming amide bonds in peptide synthesis etc. DMP is 
also a common crosslinker and is used to crosslink antibody to Protein G or A 
Sepharose. It possesses two identical groups which can react with primary 
amine groups to form stable covalent bonds. One advantage of this crosslinker 
is that it is pH-dependent. It will react rapidly with amines at alkaline pH 
values (pH 8-10) and is reversible at high pH values. 
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Figure 3.4 Crosslinking of Ku70 complex combined with TAP tag 
purification. 
 
A. The Ku70 complex was crosslinked after it was cleft from IgG beads. 
1, Control. 2, 293F-NTAP-Ku70. 
3, Control-293F crosslinked by EDC.  4, 293F-NTAP-Ku70 crosslinked by 
EDC. 
5, Control-293F crosslinked by DMP. 6, 293F- NTAP-Ku70 crosslinked by 
DMP. 
 
B. The Ku70 complex  was crosslinked when it still bound to IgG beads. 
1, Control-293F crosslinked by DMP. 2, 293F- NTAP-Ku70 crosslinked by 
DMP. 
3, Control-293F crosslinked by Formaldehyde. 4, 293F- NTAP-Ku70 





The Ku70 complex was crosslinked at two consecutive stages 
respectively. We first corsslinked it after the first-step purification when it still 
bound to IgG beads. Considering that there were some nonspecific proteins 
binding to the beads which were possible to be crosslinked to Ku70 complex,  
we carried out another experiment to crosslink the complex immediately after 
it was cleaved from IgG beads. The result showed that only DMP worked in 
both processes. The failure of  EDC in first process and  formaldehyde in 
second process may because of  the coverage of the TEV cleavage site or 
calmodulin binding domain by the crosslinked proteins. As shown in Figure 
3.4, the backgrounds were still clear and more proteins were pulled down after 
crosslinking compared with the eluate without crosslinking.  But the protein 
profiles were a little different by using different crosslinkers in different stages.  
It may be because of the preferential difference of each corsslinker for target 
proteins according to their own crosslinking mechenisms. 
 
3.3.4 Enrich of Cytoplasmic Pool of Ku70 
Ku70 is a predominant nuclear protein. The HEK293 cells stable 
expressing GFP-tagged Ku70 were observed under confocal microscope in 
different time points of the cell cycle.  Ku70 stays in nucleus during the whole 
cell cycle. It has been observed to transiently translocated to cytoplasm in M 
phase (Figure 3.5). Although the cytoplasmic pool of Ku70 is less abundant, it 
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Figure 3.5 Location of Ku70 during Cell cycle 
 
HEK293 cells stablely expressing GFP-tagged Ku70 were synchronized by 
40ng/ml nocodazole for 12h and then trypsinized and replanted to release cells 
from nocodazole (0h). The cells were then observed under confocal 
microscope at time point 8h, 18h, 23h. Flow cytometry analysis showed that 
most of cells in each time point were in M phase (0h, A), G1 phase (8h, B), S 
phase (18h, C) and G2/M phase (23h, D) 
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in cytoplasm largely remain unknown. In order to pull down more cytoplasmic 
partners of Ku70, we enriched cytoplasmic Ku70 by separating cytoplasmic 
proteins from nuclear proteins, arresting cells in G2/M phase or constructing 
Ku70 mutant K533A to prevent it from translocating to nucleus. The lysates 
were purified by TAP procedure. Ku70 was demonstrated to exist in 
cytoplasm by western blot analysis (Figure 3.6, A). The profiles of eluates 
from cytoplasmic and nuclear proteins were different (Figure 3.6, B). The 
region composed of 18 amino acid residues (positions 539-556) of Ku70 was 
reported to be the intrinsic nuclear localization signal (NLS) (Koike, 2002). It 
will help Ku70 translocate to nucleus by binding to specific NLS receptors. 
We constructed 2 mutants which replaced glutamic acid  in position 548 and 
lysine in position 553 by alanine. The change of amino acids will alter the 
configuration of this region so that to prevent the translocation of Ku70 from 
cytoplasm to nucleus.  HEK293 cells transfected by GFP-tagged mutants 
E548A and K553A were observed under confocal microscope.  As shown in 
Figure 3.7 (B, C), K553A mutant prevented Ku70 translocation to the nucleus 
while E548A mutation could not stop the translocation of Ku70 to the nucleus. 
 
3.3.5 Reduction of Protein Complexity in Eluate Submitting to Mass 
Spectrometry 
The number of proteins identified in mixture usually depends on the 
complexity of mixture. In general, the simpler the sample is, the more accurate  
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Figure 3.6 Cytoplasmic and nuclear pool of Ku70 
 
A. 293F cells expressing NTAP-tagged Ku70 were lysed. cytoplasmic proteins 
were separated from nuclear proteins. Ku70 was detected by antibody in raw 
cell lysate. 
 
B Raw cell lysates containing cytoplasmic proteins or nuclear proteins were 
purified by TAP procedure. The eluates were separated in 4%-12% SDS-
PAGE gel. 
 
1, Control-293F, cytoplasmic fraction.  2, 293F-NTAP-Ku70, cytoplasmic 
fraction 
3, Control-293F, nuclear fraction.   4, 293F-NTAP-Ku70, nuclear fraction.    
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Figure 3.7 Location of Ku70 and its mutants 
 
HEK293 cells transfected by GFP-tagged wild type Ku70 and its mutants 
E548A and K553A were observed under confocal microscope. 
A. wild type Ku70   B. E548A   C. K553A 
 1             2             3             4  
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the mass spectrometry analysis will be. Fractionation of a complex protein 
mixture to multiple simpler fractions is the strategy to improve the 
detectability of low abundant proteins.  In order to reduce the complexity of 
proteins in eluate, we eluted proteins bound to calmodulin beads by a series of 
NaCl gradient elution buffers (50mM ABB pH 8.0 with 250mM, 500mM or 
750mM NaCl). Proteins were eluted gradually along with the increase of salt 
concentration (Figure 3.8).  
 
3.3.6 Identification of Ku70 Complex by Mass Spectrometry 
The shotgun proteomics approach  was applied to analyze the eluate 
recovered from the TAP purification. The complex was first digested by 
trypsin. Resulting peptides were then separated by a C18 nanocolumn and 
sequenced by tandem mass spectrometry. The LC gradient time was either 60 
minutes or 180 minutes to improve the separation of peptides. MS/MS data 
were analyzed by MASCOT with IPI human database. In order to reduce the 
complexity of the mixture, we also separated the eluate from the TAP 
purification by 4%-12% SDS-PAGE. The lane was then divided into several 
equal size sections without any staining to prevent fixing of proteins in gel. 
Each section was subjected to in-gel digestion. The resulting peptide 
recovered from in-gel digestion was analyzed by LC-MS/MS. 
We had run multiple pull-down experiments with different 
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Figure 3.8 Elution of proteins by NaCl gradient elution buffer 
 
1, 250 mM NaCl in elution buffer 
2, 500 mM NaCl in elution buffer 
3, 750 mM NaCl in elution buffer 




identified in every experiment. Ku70 was identified with the highest score. 
Ku80 was the second most abundant protein identified in every pull down 
because Ku80 is known to form heterodimer with Ku70. DNA-dependent 
protein kinase catalytic subunit, another member protein of DNA-PK, was also 
found among the most abundant proteins in the complex. All histone proteins 
were detected with very high scores. Many subunits of 40S ribosomal protein 
and 60S ribosomal protein were also detected with high scores. We also 
detected some subunits of tubulin, nuclear ribonucleoproteins and heat shock 
proteins. Besides, 94 other proteins were found with peptides score 50 or 
above. (Table 3.1, 3.2). In total, we detected 151 proteins interacting with 
Ku70 under different conditions. 
The IPI accession number for each protein was then converted to gene 
symbol with IPI cross reference table. The 151 genes were then inputted into 
Panther Database to classify these proteins according to their molecular 
functions, biological processes or pathways they are involved in. 
All the 151 proteins in the complex are associated with 19 molecular 
functions, 19 biological processes and 23 pathways (Figure 3.9, 3.10, 3.11, 
Table 3.3, 3.4, 3.5). The proteins under each biological process and pathway 
were listed (Table 3.6, 3.7). Our result showed that Ku70 interacted with 81 
proteins in the biological process of nucleoside, nucleotide and nucleic acid 
metabolism (Table 3.8).  This is consistent with the known Ku70 biological 
functions in DNA repair, telomere maintenance and transcriptional regulation. 
As shown in tables, among these proteins, 15 proteins are involved in DNA 
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repair that is the major function of Ku70. Seventeen Ku70 interacting proteins 
were found to play roles in apoptosis, this is consistent with recent reports that 
Ku70 is a regulator of apoptosis. Furthermore, the postulated biological 
processes and pathways both suggested that Ku70 is an important protein in 
cell cycle, signal transduction and transcription regulation. Moreover, Ku70 
also associated with proteins in p53 pathway. As p53 mutation and 
deregulation is involved in up to 50% of human tumors and p53 dramatically 
regulates the cellular response to ionizing radiation and chemotherapeutic 
drugs, the result strongly evidenced that Ku70 may play a pivotal role in 
cancer biology. 
 
3.3.7 Validation of Search Result of Mass Spectrometry 
Ku80 is a well-known Ku70 binding partner which forms heterodimer 
with Ku70 to participate in many biological processes. Ku80 was identified to 
be the second most abundant protein in the complex after Ku70.  We had 
validated the Ku80 by carrying out a western blot analysis on the eluate from 
TAP purification.  As shown in Figure 3.12 (A), Ku80 could be detected by 
Anti-human Ku80 antibody (Santa Cruz) in the eluate. This demonstrated that 
TAP tag purification couple to mass spectrometry analysis is a specific and 




Figure 3.9  Molecular functions modulated by all complex proteins
  Cell adhesion molecule (MF00040)  
  Cell junction protein (MF00276)  
  Chaperone (MF00077)  
  Cytoskeletal protein (MF00091)  
  Hydrolase (MF00141)  
  Isomerase (MF00166)  
  Kinase (MF00107)  
  Ligase (MF00170)  
  Miscellaneous function (MF00197)  
  Molecular function unclassified (MF00208) 
1   Nucleic acid binding (MF00042)  
  Protease (MF00153)  
  Select calcium binding protein (MF00188) 
1   Select regulatory molecule (MF00093)  
  Signaling molecule (MF00016)  
  Transcription factor (MF00036)  
  Transfer/carrier protein (MF00087)  
  Transferase (MF00131)  




   
 Figure 3.10  Biological processes modulated by all complex proteins 
  Apoptosis (BP00179)  
  Biological process unclassified (BP00216)  
  Cell adhesion (BP00124)  
  Cell cycle (BP00203)  
  Cell proliferation and differentiation (BP00224)  
  Cell structure and motility (BP00285)  
  Developmental processes (BP00193)  
  Immunity and defense (BP00148)  
  Intracellular protein traffic (BP00125)  
  Lipid, fatty acid and steroid metabolism (BP00019)  
  Muscle contraction (BP00173)  
  Neuronal activities (BP00166)  
  Nitrogen metabolism (BP00090)  
  Nucleoside, nucleotide and nucleic acid metabolism (BP00031)  
  Oncogenesis (BP00281)  
  Protein metabolism and modification (BP00060)  
  Sensory perception (BP00182)  
  Signal transduction (BP00102)  





     Figure 3.11  Pathways modulated by all complex proteins
 Angiogenesis (P00005)  
 Apoptosis signaling pathway (P00006)  
 DNA replication (P00017)  
 EGF receptor signaling pathway (P00018)  
 Endothelin signaling pathway (P00019)  
 FAS signaling pathway (P00020)  
 FGF signaling pathway (P00021)  
 Huntington disease (P00029)  
 Hypoxia response via HIF activation (P00030)  
 Inflammation mediated by chemokine and cytokine signaling pathway (P00031)  
 Insulin/IGF pathway-protein kinase B signaling cascade (P00033)  
 Interleukin signaling pathway (P00036)  
 Notch signaling pathway (P00045)  
 Oxidative stress response (P00046)  
 PDGF signaling pathway (P00047)  
 PI3 kinase pathway (P00048)  
 Parkinson disease (P00049)  
 Ras Pathway (P04393)  
 T cell activation (P00053)  
 VEGF signaling pathway (P00056)  
 Wnt signaling pathway (P00057)  
 p53 pathway feedback loops 2 (P04398)  
 p53 pathway (P00059)  
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Figure 3.12  
 
The eluate from TAP purification was separated by SDS-PAGE and then was 
transferred to a PVDF membrane. The exist of complex proteins was tested by 
antibodies. 
A. IB: anti-Ku80.   B. IB: anti-parp 
1, Control-293F with empty vetctor.   2, 293F-NTAP-Ku70 
 
The eluates from TAP purification of NTAP-tagged wild type Ku70 and three 
mutants: L385R, E548A and K553A were separated by SDS-PAGE and then 
were transferred to PVDF membrane.  
C. Ku80 binding ability was tested. IB: Ku80. 
D. PARP was tested. IB: anti-Parp. 
1, Control-293F with empty vetctor.   2, 293F-NTAP-Ku70 







3.3.8 Poly [ADP-ribose] Polymerase (PARP) May Interact With Ku70 
Through Ku80 
The poly [ADP-ribose] polymerase (PARP) in the eluate from TAP 
purification was also detected by anti-PARP antibody (Figure 3.12, B). To 
further explore how PARP interacts with Ku70, we constructed another Ku70 
mutant L385R.  The region from residue position 378 to 482 of Ku70 were 
considered to be the Ku80-binding domain (Koike, 2002). The mutation in 
L385 significantly impairs its ability to interact with Ku80 (Figure 3.12, C). 
We tested for PARP in the eluate from three Ku70 mutants: L385R, E548A 
and K553A and found that PARP could be detected in the eluate of E548A 
and K553A, but did not exist in the eluate of L385R (Figure 3.12, D). This 
suggested that PARP may not interact with Ku70 directly. It may interact with 
Ku80, and pull down by Ku70 through Ku80 because when Ku80 interacting 
domain of Ku70 was mutated, PARP could not be detected in the Ku70 
complex. 
 
3.3.9 Role of Ku70 in Apoptosis 
Ku70 was reported as a mediator of Bax which induced apoptotic 
pathway. We also found several proteins in Ku70 complex function in 
apoptotic pathway.  To investigate the effects of overexpression of Ku70 on 
cell death, we used HDAC inhibitors, Trichostatin A (TSA), a hydroxyamic 
acid derivative originally developed as an antifungal agent, and SAHA to treat 
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the HEK293F cell that overexpressed Ku70. Both compounds suppress cell 
growth, induce differentiation and apoptosis in different tumor types.  As 
shown in Figure 3.13, overexpression of Ku70 did not induce cell death when 
cells were treated by these HDAC inhibitors.  Although more Ku70 were 
acetylated by HDACIs in Ku70 overexpression cells which should release Bax 
to trigger apoptosis, the amount of nonacetylated Ku70 was also higher 
abundant than normal cells to sequester Bax. As a result, the ratio of 
nonacetylated and acetylated Ku70 remained unchange between normal 293F 
cells and HDACI treated Ku70 overexpressed 293F cells so that their cell 
death curves nearly overlapped. 
 
3.4 Discussion 
3.4.1 Affinity Purification 
Nearly all proteins exert their molecular functions by interacting with 
one another to form a large protein complex. Elucidation of the composition of 
these protein complexes will help greatly to clarify protein function or 
pathways they involve in. It has increasingly become one of the focuses of 
proteomic research. To detect the protein-protein interactions in higher 
eukaryotes, methods that are capable of rapidly and efficiently purifying intact 
protein complexes will be required. In our study, we applied the one step 
FLAG-tag purification and two steps tandem affinity tag purification method 











































SAHA(uM) 0.1%DMSO 0.1 0.5 1 2.5 5 7.5 10 
TSA(uM) 0.1%DMSO 0.1 0.5 1 2.5 5 10   
 
Figure 3.13 HDACI induces cell death in 293F cells and Ku70 
overexpressed 293F cells.  
 
293F cells with empty vector and 293F cells stablely expressing GFP-tagged 
Ku70 were treated with various concentrations of SAHA or TSA as indicated 
for 60h. Cell viability was determined by MTS assay. Results are expressed as 
the percentage of viable cells compared with vehicle treated controls. 
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demonstrated to be efficient for Ku70 complex pull down.  Nonspecific 
bindings were greatly reduced because of the specific and mild elution. 
This generic tandem affinity tag purification method is not only limited 
to identify protein-protein interactions. It will also facilitate analysis and 
identification of post-translational modifications of proteins which we will 
describe and discuss in chapter 4. 
Some papers reported that CBP tag did not work in their systems 
(Knuesel et al., 2003; Kim, S. C. et al., 2006). The reason may be the binding 
of endogenous calmodulin to CBP will block its ability to bind to calmodulin 
beads.  It depends on the cell lines which have different expression levels of 
endogenous calmodulin and also the abundance of the target proteins. Our 
target protein Ku70 is relatively high abundant in HEK293 cell that reduces 
the interference of endogenous calmodulin. 
Although the TAP tag greatly improved the specificity of purification, 
we encountered several problems.  Some calcium binding proteins besides 
calmodulin in mammalian cells also bound to CBP. These proteins formed a 
feint that they were also the partners of Ku70. In order to avoid the 
interference of these nonspecific bindings, we abtained a protein list from the 
control sample which was transfected by the empty vector only with TAP tag 
domain. The detected non-specific proteins were removed from the Ku70 
complex list. The interference of immunoglobulin is another problem in this 
system.  High levels of immunoglobulin protein washed out from IgG beads 
can easily mask the lower abundance peptides derived from low stoichiometry 
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interacting partners in the MS run. The signal of high levels of Ku70 and Ku80 
in the eluates from TAP tag purification also suppressed lower abundant 
peptides. To solve this problem, we eluted proteins bound to calmodulin beads 
by a series of NaCl gradient elution buffers. Therefore, the binding proteins 
were divided into several fractions according to their binding strength to Ku70 
complex. Another solution was to separate the proteins by gel according to 
their molecular weight. As described above, gel lane containing all proteins 
was divided into several equal size sections and was digested individually. 
 
3.4.2 Core Ku70 Complex And Other Regulated Ku70 Complex 
Ku70 widely expresses in various mammalian systems and the Ku 
complex has been described as various terms such as nuclear factor IV (NFIV), 
transferrin receptor promoter element binding factor (TREF), proximal 
sequence element 1 (PSE 1), end binding protein (EBP), and human DNA 
helicase II (HDHII) (Devries et al., 1989; Roberts et al., 1989; Knuth et al., 
1990; Stuiver et al., 1990; Falzon et al., 1993; Tuteja, N. et al., 1994). Many 
direct and indirect evidences imply that Ku70 is not only a DNA binding 
protein, but in fact it is a multifunctional protein and a member of a multigene 
family. The Ku70 interacting proteins from our experiments can be classified 
into several biological processes, and agrees with previously reported Ku70 
functions. However, we have identified many novel Ku70 interacting proteins. 
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Here we use the term Ku70 complex loosely, which refers to proteins 
that interact with Ku70 directly or indirectly. However, proteins bind to Ku70 
with different affinity. Some proteins bind to Ku70 tightly and are always 
puried together with Ku70, such as Ku80, DNA-dependent protein kinase 
catalytic subunit and Poly[ADP-ribose] polymerase. Some proteins bind to 
Ku70 transiently, indirectly or only in specific conditions. The interactions 
may be easy to be disrupted during cell lysis or the procedure of purification. 
Furthermore, one or a set of proteins may appear in multiple complexes and 
complex will interact with other complexes which make the situation more 
complicated. In this case, Yi Wang et al. have put forward the concept “Core 
complex” and “regulated complex” (Waksman, 2005). Proteins in core 
complex are always together in cells and are not disrupted by buffers 
containing high concentration of salt and detergents. Other proteins can 
interact with the core protein complex to form the regulated complexes. There 
is only one core complex, but there are many regulated complexes in which 
different proteins can join the core complex to assume different functions. 
The identified Ku70 interacting proteins depended on experimental 
conditions. High abundant proteins and stable members were always detected 
such as Ku70, Ku80, histones, ribosomal proteins etc. but low abundant 
proteins were varied partly because of the regulated complexes. To ensure 
pulling down of true positive Ku70 interacting partners, we compared the 
results from repeated and independent experiments. Proteins which have been 
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identified in multiple independent experiments but did not appear in control, 
and with MASCOT score higher more than 50 were treated as true positives. 
Based on our data, we propose a hypothesis that Ku70, Ku80, DNA-
dependent protein kinase catalytic subunit, PARP1,2, RPA1,2,3 and werner 
syndrome protein form the core Ku70 complex. All of them have been 
reported to be the partners of Ku70 by other researchers. They mainly involve 
in the DSB repair by NHEJ pathway (Critchlow et al., 1997; Weinfeld et al., 
1997; Ismail et al., 2004). Other proteins may form regulated complexes with 
Ku70 transiently or in specific condition to exert particular functions, such as 
Ku70-PCAF and Ku70-HDACs complexes. PCAF can acetylate Ku70 while 
HDACs can deacetylate Ku70. These two kinds of proteins exert opposite 
functions. Thus, they will never present in the complex at the same time. 
We have identified 20 known Ku70 interacting proteins which have 
been reported to interact with Ku70 directly or indirectly, these protein 
includes Ku80, PARPs, RPA proteins, DNA-PK, HSP70, DNA 
topoisomerases, PCAF, Werner syndrome protein, DNA ligase III, Histone 
deacetylase1, 2, APEX2. Nine proteins that haven’t been reported to interact 
with Ku70,  but they can form complex with other Ku70 known interacting 
proteins, including H2B, XPC, XPA, MSH6, RING and YY1-binding protein, 
actin, nuclear matrix transcription factor 4, high mobility group proteins and 
RAD23. They are the most potential candidates of functional Ku70 protein 
complex. Figure 3.14 shows the potential functional network between these 
proteins. 
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Besides the core Ku70 complex, additional participants in the DNA-
PK mediated NHEJ repair pathway were also found in our complex proteins 
such as DNA ligase III. Besides, some other DNA repair proteins such as 
centrin 2, Xeroderma pigmentosum group C complementing protein(p125) 
(XPC), Xeroderma pigmentosum, complementation group A (XPA) and 
Structural maintenance of chromosome 1-like 1 protein (Smc1L1) were also 
detected. The structural maintenance of chromosomes (SMC) family of 
proteins has been implicated in the repair of DNA double-strand breaks (DSBs) 
by homologous recombination (HR) (Schar et al., 2004). Pull down of these 
proteins suggested that Ku70 may involve in other DNA repair processes 
besides NHEJ and V(D)J recombination repair pathway. XPA can form 
complex with the core Ku70 complex member protein RPA to initiate the 
nucleotide excision repair (NER) (Frit et al., 1998). Another nucleotide 
excision repair factor xeroderma pigmentosum C (XPC) protein is associated 
with RAD23 (Hsieh et al., 2005) and is required for global genome repair,  
while both RAD23 and RPA were copurified in NER complex (Rodriguez et 
al., 1998). Human centrin 2 is a component of the nucleotide excision repair 
system, as a subunit of the heterotrimer including xeroderma pigmentosum 
group C protein (XPC) and hHR23B. The pull down of RAD23, XPC and 
centrin2 complex strongly indicated that Ku70 may play important role in 




Figure 3.14 Protein-Protein interactions between Ku70 and its associated 
proteins. 
The core Ku70 complex is circled in blue. The NER complex is circled in red. 

































RING1 and YY1-binding protein
Centrin-2
HMG proteins








MSH6 may interact with Ku70 through PARP since poly(ADP-ribose)-
binding site was identified in MSH6 as well as other proteins like p53, DNA 
ligase III etc (Pleschke et al., 2000). Ku70 was identified as part of a complex 
with ARF6 which is essential for cytokinesis (Schweitzer and D'Souza-
Schorey, 2005). Although we did not detect ARF6, 13 proteins involving in 
cell structure and motility were identified. ARF6 will also induce changes in 
actin cytoskeleton. YY1 is another known Ku70 interacting protein which 
form complex with Ku protein and is regulated in human heart failure and 
represses α myosin heavy-chain gene expression (Sucharov et al., 2004). The 
RING1 and YY1-binding protein may interact with Ku70 through YY1. Some 
papers reported that Ku70 can transiently associate with nuclear matrix and 
high mobility group proteins during V(D)J recombination (Yu et al., 1998; 
Rodgers et al., 2002a). 
 
3.4.3 Analysis of Other Regulated Complex 
Histones have never been reported to interact with Ku70 or DNA-PK. 
Only H2B was reported to be down-regulated by DNA-PK in response to 
DNA damage through modulation of octamer transcription factor 1 (Oct1) 
(Schild-Poulter et al., 2003). But we found histones were the most abundant 
proteins in the complex besides Ku80 which is known to form heterodimer 
with Ku70. Consider the downregulation of H2B by Oct1, other histones may 
also take part in the process of DNA repair. Ku70 has been reported as a 
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transcription factor that recruits DNA-PK directly to negative regulatory 
element 1 specific sequence and represses glucocorticoid-induced MMTV 
transcription (Giffin et al., 1996). It also has been shown that Ku acts as a 
potential transcription factor for RNA polymerase II (Kuhn et al., 1993). 
Binding of Ku70 to promoter sequences could occur via the carboxyl-terminal 
SAP domain (Aravind and Koonin, 2001). The modification of histones 
controls the activation and repression of gene transcription. The interaction 
between Ku70 and histones further suggests that Ku70 may participate in gene 
transcription. Consistent with this hypothesis, we found 30 proteins in the 
Ku70 complex are related to mRNA transcription. 
Another interesting finding is ribosomal proteins and nuclear 
ribonucleoproteins in Ku70 complex. The interaction between ribosomal 
proteins and Ku70, nuclear ribonucleoproteins and Ku70 have not been 
reported. Nineteen subunits of 60S ribosomal proteins, 10 subunits of 40S 
ribosomal proteins and 9 subunits of nuclear ribonucleoproteins were detected 
in our experiments. The major function of ribosomal proteins is protein 
biosynthesis. The heterogeneous nuclear ribonucleoproteins (hnRNP) are a 
family of proteins which share common structural domains, and extensive 
research has shown that they have central roles in DNA repair, telomere 
biogenesis, cell signaling and in regulating gene expression at both 
transcriptional and translational levels. The result suggested Ku70 may play 
roles in protein synthesis and regulating gene expression through hnRNP. 
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Recent reports showed that Ku70 plays central role in apoptosis 
pathway. Although our assay did not show significant difference between 
normal cell and Ku70 overexpressed HEK293 cells under the treatment of 
HDAC inhibitors, other recent reports provide strong evidence that Ku70 is 
important in mediating apoptosis (Cohen et al., 2004; Subramanian et al., 
2005). Ku70 was reported to bind to the pro-apoptosis protein Bax and 
sequester Bax-mediated apoptosis by preventing its relocalization to the 
mitochondria. Our data showed that 17 proteins in the Ku70 complex 
involving in apoptotic process including pro-apoptosis proteins FMR1, SMG1, 
LGALS1, FXR1, FXR2 and anti-apoptosis proteins AVEN, AKT1, 2, 3, 
HDAC1, 2, BAG3; however, Bax was not found in our list suggesting the 
interaction between Bax and Ku70 is transient and weak. This also shows that 
the interaction between Ku70 and other apoptosis proteins that have been 
identified in our pull down is stronger than Bax.  Therefore, Ku70 may 
regulate cellular apoptosis in other ways than simply sequestering Bax. 
Ku70 was also proposed to act as either a tumor suppressor or an 
oncoprotein. It may act with other oncoproteins or tumor suppressors to affect 
the oncogenic state (Gullo et al., 2006). Altered expression of  Ku70 was 
found in many tumors. Overexpression of Ku proteins promotes oncogenic 
phenotypes, such as hyperproliferation or resistance to apoptosis. Deficient or 
low expression of Ku leads to tumorigenesis. Recent studies have also 
provided some evidence that defects in the two major DNA DSBR pathways 
are related to the development of cancer (Khanna and Jackson, 2001). The 
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involvement of Ku70 associated proteins in p53 pathway further demonstrated 
the relationship between Ku70 and the development of cancer. We also found 
2 oncoproteins in the complex: MAGEB18 and FUS. We detected PARP1 and 
2 in the complex and demonstrated the interaction between PARP and Ku80. 
PARP-1 is a nuclear enzyme that catalyses the poly(ADP-ribosyl)ation of 
target proteins in response to DNA damage. It is suggested to play a vital role 
in DNA repair and recombination, cell death, proliferation and stabilization of 
the genome (Lindahl et al., 1995; Herceg and Wang, 2001). Recent report 
showed that PARP-1 not only plays important role in NHEJ repair pathway, 
but also in suppression of liver tumorigenesis together with Ku80 (Tong et al., 
2002). These findings all strongly suggested Ku70 may be a tumor suppressor 
or an oncoprotein. More excitingly, the relationship between Ku70 and cancer 
makes Ku70 an important candidate target for anticancer drug development. 
Paillard and Strauss predicted a possible role of Ku70 in replication 
forks movement during  DNA replication (Paillard and Strauss, 1991). Ku was 
reported to interact with human DNA containing replication origin (Toth et al., 
1993). Our result showed that the critical proteins in DNA replication process 
such as topoisomerase I and topoisomeraseII, replication protein A as well as 
WRN, MCM3 etc. were associated with Ku70. These findings suggested that 
Ku70 may have an important role in the initiation of DNA replication. 
It was reported that the subcellular localization of Ku70 is cell-cycle 
dependent which was also demonstrated by our own experiments. Ku70 was 
distributed in both the nucleus and the cytoplasm in M phase while it only 
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restricted to nucleus in other phases. The cell cycle was reported to be blocked 
at G2 phase in yeast Ku70-deficient strain, indicating the potential role of 
Ku70 in the regulation of cell cycle (Feldmann and Winnacker, 1993). Our 
result also strongly suggested the involvement of Ku70 in cell cycle regulation. 
Twenty-nine proteins in the Ku70 complex are related to cell cycle regulation. 
Ku70 is a subunit of DNA-PK complex that is reported to play an 
important role in signal transduction pathway (Hartley et al., 1995). The 
involvement of 14 Ku70 associated proteins in cell signaling indicated that 
Ku70 may take part in the pathway directly. In fact, Ku70 was reported as an 
important component of signal transduction pathways according to its 
response to different external stimuli (Fewell and Kuff, 1996). 
Five proteins in the complex involve in Huntington disease (HD) 
pathway. Huntington's disease is an autosomal dominantly inherited 
neurodegenerative disorder caused by a polyglutamine repeat expansion. 
Recent studies showed that transcriptional dysregulation may be the main 
reason for HD pathogenesis. The control of eukaryotic gene expression 
depends on the modification of histone. We have indicated that Ku70 may 
interact with histones and play roles in gene transcription so that connected to 
HD. Interestingly, recent studies have shown a therapeutic role for histone 





In conclusion, we applied tandem affinity purification method to pull 
down Ku70 complex in HEK293F cells. There were 151 proteins or subunits 
being found in the complex. Most of them involve in DNA repair, apoptosis, 
cell cycle regulation, gene transcription and signal transduction. Many Ku70 
associated proteins participate in p53 pathway indicating the relationship 
between Ku70 and the development of cancer. PARP was demonstrated to be 
a real partner of Ku70 and interact with Ku70 through Ku80. We proposed a 
hypothesis that Ku70, Ku80, DNA-dependent protein kinase catalytic subunit, 
PARP1,2, RPA1,2,3 and werner syndrome protein form a core protein 
complex that mainly exert the function of  DSB repair through NHEJ pathway. 
Other proteins form regulated complexes with Ku70 which are not as stable as 
the core complex or form complex in specific condition. These regulated 
complexes assume multiple functions of Ku70. Our result provided clues for 
the roles of Ku70 in biological processes. The interaction between Ku70 and 









Table 3.1 Histones, ribosomal proteins, nuclear ribonucleoproteins, heat shock 
proteins and tubulins in Ku70 complex,  
Protein Name IPI No. Gene Symbol 
Histone proteins (12)     
Histone H1.1 IPI00217469   HIST1H1A 
Histone H1.2 IPI00217465   HIST1H1C 
Histone H1.4 IPI00217467   HIST1H1E 
Histone H1.5 IPI00217468   HIST1H1B 
Histone H2A type 1-A  IPI00045109   HIST2H2AA 
Histone H2A type 1-B  IPI00216730   HIST2H2AB 
Histone H2A type 1-C IPI00216456   HIST1H2AC 
Histone H2A type 1-D  IPI00255316 HIST1H2AD 
Histone H2B type 3-B IPI00166293   HIST3H2BB 
Histone H3.1 IPI00465070   HIST1H3A 
Histone H3.4 IPI00216402   HIST3H3 
Histone H4 IPI00453473.5   HIST2H4A 
Ribosomal proteins (29)     
60S ribosomal protein L4  IPI00003918 RPL4 
60S ribosomal protein L5  IPI00000494 RPL5 
60S ribosomal protein L6  IPI00329389 RPL6 
60S ribosomal protein L7  IPI00030179 RPL7 
60S ribosomal protein L8  IPI00012772 RPL8 
60S ribosomal protein L11  IPI00219150 RPL11 
60S ribosomal protein L12  IPI00024933 RPL12 
60S ribosomal protein L15  IPI00470528 RPL15 
60S ribosomal protein L17  IPI00413324 RPL17 
60S ribosomal protein L18  IPI00215719 RPL18 
60S ribosomal protein L19  IPI00025329 RPL19 
60S ribosomal protein L24  IPI00306332 RPL24 
60S ribosomal protein L26  IPI00027270 RPL26 
60S ribosomal protein L27  IPI00219155 RPL27 
60S ribosomal protein L29  IPI00419919 RPL29 
60S ribosomal protein L30  IPI00219156 RPL30 
60S ribosomal protein L31  IPI00026302 RPL31 
60S acidic ribosomal protein P1  IPI00008527 RPLP1 
60S acidic ribosomal protein P2  IPI00008529 RPLP2 
40S ribosomal protein S2  IPI00013485 RPS2 





Table 3.2 Other 94 proteins in Ku70 complex.  
40S ribosomal protein S9  IPI00221088 RPS9 
40S ribosomal protein S10  IPI00008438 RPS10 
40S ribosomal protein S11  IPI00025091 RPS11 
40S ribosomal protein S14  IPI00026271 RPS14 
40S ribosomal protein S16  IPI00221092 RPS16 
40S ribosomal protein S19  IPI00215780 RPS19 
40S ribosomal protein S23  IPI00218606 RPS23 
40S ribosomal protein S24  IPI00029750 RPS24 
Nuclear ribonucleoprotein (9)     
Heterogenous nuclear ribonucleoprotein U  IPI00025054 HNRPU 
Hetogeneous nuclear ribonucleoproteins C1/C2  IPI00216592 HNRPC 
Heterogeneous nuclear ribonucleoprotein R  IPI00012074 HNRPR 
Heterogeneous nuclear ribonucleoprotein H'  IPI00026230 HNRPH2 
Small nuclear ribonucleoprotein associated 
protein N  IPI00220360 SNRPN 
Small nuclear ribonucleoprotein B'  IPI00384173 SNRPB 
Heterogeneous nuclear ribonucleoprotein Q  IPI00402182 SYNCRIP 
Heterogeneous nuclear ribonucleoprotein K  IPI00640296 HNRPK 
Heterogeneous nuclear ribonucleoprotein C-like 1  IPI00027569 HNRPCL1 
Heat shock proteins (4)     
Heat shock protein HSP 90-alpha 2  IPI00382470 HSPCA 
Heat shock protein HSP 90-beta  IPI00414676 HSPCB 
Heat shock cognate 71 kDa protein  IPI00037070 HSPA8 
Heat shock 70 kDa protein 1  IPI00304925 HSPA1A 
Tubulin and tubulin related proteins (3)     
Tubulin alpha-2 chain  IPI00179709 TUBA2 
Tubulin alpha-6 chain  IPI00218343 TUBA6 
Tubulin family protein  IPI00646909 TUBA8 





ATP-dependent DNA helicase II, 70 kDa subunit  IPI00465430 G22P1 232043
ATP-dependent DNA helicase II 80 kDa subunit IPI00220834   XRCC5 207006
Poly [ADP-ribose] polymerase 1  IPI00449049 PARP1 4621 
Glial fibrillary acidic protein, astrocyte  IPI00443478 GFAP 4374 
K-ALPHA-1 protein  IPI00328163 K-ALPHA-1 3971 
89 
Replication protein A 70 kDa DNA-binding 
subunit  IPI00020127 RPA1 3547 
UBC protein  IPI00554749 UBB 2685 
Nuclease sensitive element-binding protein 1  IPI00031812 NSEP1 2545 
DNA-dependent protein kinase catalytic subunit  IPI00296337 PRKDC 2158 
DNA-binding protein  IPI00385699 YBX1 1950 
Vimentin  IPI00646867 VIM 1827 
BBF2H7/FUS protein (Fragment)  IPI00428056 FUS 1585 
Actin, alpha cardiac  IPI00023006 ACTC 1348 
Actin, aortic smooth muscle  IPI00008603 ACTA2 1309 
Structure-specific recognition protein 1  IPI00005154 SSRP1 1097 
Creatine kinase B-type  IPI00022977 CKB 1079 
Centrin-2  IPI00215928 CETN2 751 
DNA-binding protein A  IPI00219148 CSDA 711 
EIF4G3 protein  IPI00328268 EIF4G3 639 
DNA topoisomerase 2-alpha  IPI00218753 TOP2A 635 
Elongation factor 1-alpha 2  IPI00014424 EEF1A2 633 
EEF1A protein (Fragment)  IPI00382804 EEF1A1 592 
Replication protein A 14 kDa subunit  IPI00017373 RPA3 555 
Y-box-binding protein 2  IPI00250153 YBX2 475 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A3  IPI00339381 SMARCA3 472 
zinc finger protein 265 isoform 2  IPI00183794 ZNF265 472 
BAG-family molecular chaperone regulator-3  IPI00639961 BAG3 466 
Bcl-2-associated transcription factor 1  IPI00006079 BCLAF1 425 
Replication protein A 32 kDa subunit  IPI00646500 RPA2 388 
Dynein light chain 1, cytoplasmic  IPI00019329 DNCL1 374 
Methyl-CpG-binding protein 2  IPI00418234 MECP2 365 
nuclear matrix transcription factor 4  IPI00220697 ZNF384 342 
Galectin-1  IPI00219219 LGALS1 341 
Histone acetyltransferase PCAF  IPI00022055 PCAF 340 
Poly(A) binding protein, cytoplasmic 4  IPI00642944 PABPC4 325 
ATP-dependent RNA helicase DDX17  IPI00651653 DDX17 300 
Similar to Calcium-dependent protease, small 
subunit  IPI00025084 CAPNS1 286 
Splice Isoform Beta-2 of DNA topoisomerase 2-
beta  IPI00027280 TOP2B 279 
Splice Isoform 1 of Poly [ADP-ribose] 
polymerase 2  IPI00026497 PARP2 277 
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Splice Isoform 1 of Nucleolar RNA helicase 2  IPI00015953 DDX21 268 
Calumenin precursor  IPI00014537 CALU 267 
high mobility group AT-hook 1 isoform a  IPI00179700 HMGA1 245 
High mobility group protein HMGI-C  IPI00005996 HMGA2 243 
hepatoma-derived growth factor-related protein 2 
isoform 1  IPI00419322 HDGF2 217 
Treacle protein  IPI00298696 TCOF1 188 
FK506-binding protein 4  IPI00219005 FKBP4 181 
programmed cell death 8 isoform 2  IPI00157908 PDCD8 174 
SMARCA4 isoform 2  IPI00029822 SMARCA4 169 
Cell death regulator Aven  IPI00006904 AVEN 166 
PREDICTED: similar to Enhancer of rudimentary 
homolog  IPI00455070 CLEC2L 157 
DNA-repair protein complementing XP-C cells  IPI00156793 XPC 154 
UV excision repair protein RAD23 homolog B  IPI00008223 RAD23B 141 
DNA replication licensing factor MCM3  IPI00013214 MCM3 140 
Splice Isoform 1 of Ubiquitin conjugation factor 
E4 B  IPI00005715 UBE4B 138 
Probable ATP-dependent RNA helicase DDX5  IPI00017617 DDX5 137 
Fragile X mental retardation syndrome-related 
protein 1  IPI00016249 FXR1 134 
Splice Isoform 1 of Nuclear autoantigenic sperm 
protein  IPI00179953 NASP 131 
ATP-dependent RNA helicase DDX50  IPI00031554 DDX50 129 
desmocollin 1 isoform Dsc1b preproprotein  IPI00007425 DSC1 122 
UV excision repair protein RAD23 homolog A  IPI00008219 RAD23A 114 
Werner syndrome ATP-dependent helicase  IPI00029107 WRN 112 
Fragile X mental retardation syndrome-related 
protein 2  IPI00016250 FXR2 97 
Structural maintenance of chromosome 1-like 1 
protein  IPI00291939 SMC1L1 97 
Splice Isoform GTBP-alt of DNA mismatch 
repair protein MSH6  IPI00106847 MSH6 96 
Transcription factor SOX-11  IPI00020435 SOX11 95 
SWI/SNF-related matrix-associated actin 
dependent regulator of chromatin subfamily A5  IPI00297211 SMARCA5 91 
Splice Isoform 1 of Chromodomain helicase-
DNA-binding protein 3  IPI00373870 CHD3 86 
ligase III, DNA, ATP-dependent isoform beta 
precursor  IPI00000156 LIG3 83 











Nucleosome assembly protein 1-like 1  IPI00023860 NAP1L1 77 
Annexin A1  IPI00549413 ANXA1 76 
remodeling and spacing factor 1  IPI00290652 HBXAP 75 
Transcriptional repressor p66 beta  IPI00103554 GATAD2B 74 
Splice Isoform 3 of Enhancer of polycomb 
homolog 1  IPI00552203 EPC1 71 
Histone deacetylase 1  IPI00013774 HDAC1 69 
Centaurin-delta 1  IPI00292471 CENTD1 62 
Chromodomain-helicase-DNA-binding protein 2  IPI00023109 CHD2 62 
Histone deacetylase 2  IPI00289601 HDAC2 62 
RAC-alpha serine/threonine-protein kinase  IPI00012866 AKT1 60 
RAC-beta serine/threonine-protein kinase  IPI00012870 AKT2 60 
Splice Isoform 1 of RAC-gamma 
serine/threonine-protein kinase  IPI00031747 AKT3 60 
Rho GDP-dissociation inhibitor 1  IPI00003815 ARHGDIA 60 
Splice Isoform 2 of Mitogen-activated protein 
kinase kinase kinase 9  IPI00179189 MAP3K9 60 
Splice Isoform 1 of Histone-lysine N-
methyltransferase, H4 lysine-20 specific  IPI00288890 SET8 58 
Melanoma-associated antigen B18  IPI00065350 MAGEB18 57 
DNA-(apurinic or apyrimidinic site) lyase 2  IPI00083281 APEX2 56 
Splice Isoform 5 of GTPase-activating Rap/Ran-
GAP domain-like 1  IPI00456723 GARNL1 55 
DNA topoisomerase I  IPI00413611 TOP1 54 
Splice Isoform 6 of Fragile X mental retardation 1 
protein  IPI00412343 FMR1 53 
Splice Isoform 1 of cAMP-specific 3',5'-cyclic 
phosphodiesterase 4D  IPI00002449 PDE4D 53 
RING1 and YY1-binding protein  IPI00296594 RYBP 51 
nadrin isoform 1  IPI00064767 ARHGAP17 50 
PI-3-kinase-related kinase SMG-1  IPI00556369 SMG1 50 
DNA-repair protein complementing XP-A cells  IPI00009694 XPA 50 
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Table 3.3 Molecular functions modulated by all complex proteins  
 
1 Nucleic acid binding (MF00042) 103 65.60% 50.70%
2 Transcription factor (MF00036) 14 8.90% 6.90% 
3 Select regulatory molecule (MF00093) 9 5.70% 4.40% 
4 Cytoskeletal protein (MF00091) 9 5.70% 4.40% 
5 Chaperone (MF00077) 7 4.50% 3.40% 
6 Kinase (MF00107) 7 4.50% 3.40% 
7 Transferase (MF00131) 6 3.80% 3.00% 
8 Molecular function unclassified (MF00208) 6 3.80% 3.00% 
9 Signaling molecule (MF00016) 5 3.20% 2.50% 
10 Select calcium binding protein (MF00188) 4 2.50% 2.00% 
11 Miscellaneous function (MF00197) 4 2.50% 2.00% 
12 Hydrolase (MF00141) 4 2.50% 2.00% 
13 Isomerase (MF00166) 3 1.90% 1.50% 
14 Cell adhesion molecule (MF00040) 3 1.90% 1.50% 
15 Transfer/carrier protein (MF00087) 2 1.30% 1.00% 
16 Cell junction protein (MF00276) 2 1.30% 1.00% 
17 Transporter (MF00082) 1 0.60% 0.50% 
18 Ligase (MF00170) 1 0.60% 0.50% 
19 Protease (MF00153) 1 0.60% 0.50% 
 
Table 3.4 Biological processes modulated by all complex proteins  
 
1 Nucleoside, nucleotide and nucleic acid metabolism (BP00031) 81 51.60% 27.30%
2 Protein metabolism and modification (BP00060) 54 34.40% 18.20%
3 Cell cycle (BP00203) 29 18.50% 9.80% 
4 Apoptosis (BP00179) 17 10.80% 5.70% 
5 Signal transduction (BP00102) 14 8.90% 4.70% 
6 Cell structure and motility (BP00285) 13 8.30% 4.40% 
7 Developmental processes (BP00193) 13 8.30% 4.40% 
8 Immunity and defense (BP00148) 13 8.30% 4.40% 
9 Intracellular protein traffic (BP00125) 10 6.40% 3.40% 
10 Cell proliferation and differentiation (BP00224) 5 3.20% 1.70% 
11 Transport (BP00141) 5 3.20% 1.70% 
12 Nitrogen metabolism (BP00090) 4 2.50% 1.30% 
13 Cell adhesion (BP00124) 4 2.50% 1.30% 
14 Biological process unclassified (BP00216) 3 1.90% 1.00% 
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15 Neuronal activities (BP00166) 2 1.30% 0.70% 
16 Oncogenesis (BP00281) 2 1.30% 0.70% 
17 Muscle contraction (BP00173) 1 0.60% 0.30% 
18 Lipid, fatty acid and steroid metabolism (BP00019) 1 0.60% 0.30% 
19 Sensory perception (BP00182) 1 0.60% 0.30% 
 
Table 3.5 Pathways modulated by all complex proteins  
 
1 p53 pathway (P00059) 9 5.70% 10.50%
2 Apoptosis signaling pathway (P00006) 7 4.50% 8.10%
3 p53 pathway feedback loops 2 (P04398) 5 3.20% 5.80%
4 Huntington disease (P00029) 5 3.20% 5.80%
5 Wnt signaling pathway (P00057) 5 3.20% 5.80%
6 FAS signaling pathway (P00020) 5 3.20% 5.80%
7 Insulin/IGF pathway-protein kinase B signaling cascade (P00033) 4 2.50% 4.70%
8 EGF receptor signaling pathway (P00018) 4 2.50% 4.70%
9 DNA replication (P00017) 4 2.50% 4.70%
10 Angiogenesis (P00005) 3 1.90% 3.50%
11 Interleukin signaling pathway (P00036) 3 1.90% 3.50%
12 Inflammation mediated by chemokine and cytokine signaling pathway (P00031) 3 1.90% 3.50%
13 Hypoxia response via HIF activation (P00030) 3 1.90% 3.50%
14 Endothelin signaling pathway (P00019) 3 1.90% 3.50%
15 PI3 kinase pathway (P00048) 3 1.90% 3.50%
16 PDGF signaling pathway (P00047) 3 1.90% 3.50%
17 Ras Pathway (P04393) 3 1.90% 3.50%
18 VEGF signaling pathway (P00056) 3 1.90% 3.50%
19 T cell activation (P00053) 3 1.90% 3.50%
20 FGF signaling pathway (P00021) 3 1.90% 3.50%
21 Parkinson disease (P00049) 2 1.30% 2.30%
22 Oxidative stress response (P00046) 1 0.60% 1.20%
23 Notch signaling pathway (P00045) 1 0.60% 1.20%
 
Table is read as: Category name (Accession): # genes; Percent of gene hit 
against total # genes; Percent of gene hit against total # Pathway hits  
 




Nucleoside, nucleotide and nucleic acid metabolism (BP00031) 81 
GeneID:84717 HDGF2 hepatoma-derived growth factor-related protein 2;HDGF2 
GeneID:10492 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein;SYNCRIP 
GeneID:27301 APEX2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2;APEX2 
GeneID:9406 ZNF265 zinc finger protein 265;ZNF265 
GeneID:2626 GATA4 GATA binding protein 4;GATA4 
GeneID:1107 CHD3 chromodomain helicase DNA binding protein 3;CHD3 
GeneID:50810 HDGF2 hepatoma-derived growth factor, related protein 3;HDGFRP3 
GeneID:3980 LIG3 ligase III, DNA, ATP-dependent;LIG3 
GeneID:10236 HNRPR heterogeneous nuclear ribonucleoprotein R;HNRPR 
GeneID:5886 RAD23A RAD23 homolog A (S. cerevisiae);RAD23A 
GeneID:8850 PCAF p300/CBP-associated factor;PCAF 
GeneID:7155 TOP2B topoisomerase (DNA) II beta 180kDa;TOP2B 
GeneID:3065 HDAC1 histone deacetylase 1;HDAC1 
GeneID:6638 SNRPN small nuclear ribonucleoprotein polypeptide N;SNRPN 
GeneID:3190 HNRPK heterogeneous nuclear ribonucleoprotein K;HNRPK 
GeneID:8243 SMC1L1 SMC1 structural maintenance of chromosomes 1-like 1 (yeast);SMC1L1 
GeneID:51773 HBXAP hepatitis B virus x associated protein;HBXAP 
GeneID:23429 RYBP RING1 and YY1 binding protein;RYBP 
GeneID:7486 WRN Werner syndrome;WRN 
GeneID:4673 NAP1L1 nucleosome assembly protein 1-like 1;NAP1L1 
GeneID:7153 TOP2A topoisomerase (DNA) II alpha 170kDa;TOP2A 
GeneID:6597 SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4;SMARCA4 
GeneID:6664 SOX11 SRY (sex determining region Y)-box 11;SOX11 
GeneID:6628 SNRPB small nuclear ribonucleoprotein polypeptides B and B1;SNRPB 
GeneID:1106 CHD2 chromodomain helicase DNA binding protein 2;CHD2 
GeneID:5144 PDE4D phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila);PDE4D 
GeneID:3183 HNRPC heterogeneous nuclear ribonucleoprotein C (C1/C2);HNRPC 
GeneID:1655 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5;DDX5 
GeneID:8467 SMARCA5 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5;SMARCA5 
GeneID:7520 XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku 
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autoantigen, 80kDa);XRCC5 
GeneID:7508 XPC xeroderma pigmentosum, complementation group C;XPC 
GeneID:6118 RPA2 replication protein A2, 32kDa;RPA2 
GeneID:2547 G22P1 X-ray repair complementing defective repair in Chinese hamster cells 6 (Ku autoantigen, 70kDa);XRCC6 
GeneID:2956 MSH6 mutS homolog 6 (E. coli);MSH6 
GeneID:3066 HDAC2 histone deacetylase 2;HDAC2 
GeneID:5887 RAD23B RAD23 homolog B (S. cerevisiae);RAD23B 
GeneID:4172 MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae);MCM3 
GeneID:3192 HNRPU heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A);HNRPU 
GeneID:3188 HNRPH2 heterogeneous nuclear ribonucleoprotein H2 (H');HNRPH2 
GeneID:4904 NSEP1,YBX1 Y box binding protein 1;YBX1 
GeneID:387893 SET8 PR/SET domain containing protein 8;SET8 
GeneID:343069 HNRPCL1 heterogeneous nuclear ribonucleoprotein C-like 1;HNRPCL1 
GeneID:9188 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21;DDX21 
GeneID:9513 FXR2 fragile X mental retardation, autosomal homolog 2;FXR2 
GeneID:142 PARP1 poly (ADP-ribose) polymerase family, member 1;PARP1 
GeneID:8761 PABPC4 poly(A) binding protein, cytoplasmic 4 (inducible form);PABPC4 
GeneID:51087 YBX2 Y box binding protein 2;YBX2 
GeneID:10521 DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17;DDX17 
GeneID:25885 RPA1 polymerase (RNA) I polypeptide A, 194kDa;POLR1A 
GeneID:8087 FXR1 fragile X mental retardation, autosomal homolog 1;FXR1 
GeneID:80314 EPC1 enhancer of polycomb homolog 1 (Drosophila);EPC1 
GeneID:57459 GATAD2B GATA zinc finger domain containing 2B;GATAD2B 
GeneID:6596 SMARCA3 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 3;SMARCA3 
GeneID:6749 SSRP1 structure specific recognition protein 1;SSRP1 
GeneID:5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide;PRKDC 
GeneID:7150 TOP1 topoisomerase (DNA) I;TOP1 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:4678 NASP nuclear autoantigenic sperm protein (histone-binding);NASP 
GeneID:8531 CSDA cold shock domain protein A;CSDA 
GeneID:4204 MECP2 methyl CpG binding protein 2 (Rett syndrome);MECP2 
GeneID:10038 PARP2 poly (ADP-ribose) polymerase family, member 2;PARP2 
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GeneID:2332 FMR1 fragile X mental retardation 1;FMR1 
GeneID:6117 RPA1 replication protein A1, 70kDa;RPA1 
GeneID:79009 DDX50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50;DDX50 
GeneID:8350 HIST1H3A histone 1, H3a;HIST1H3A 
GeneID:8290 HIST3H3 histone 3, H3;HIST3H3 
GeneID:54606 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 56;DDX56 
GeneID:7507 XPA xeroderma pigmentosum, complementation group A;XPA 
GeneID:3008 HIST1H1E histone 1, H1e;HIST1H1E 
GeneID:3009 HIST1H1B histone 1, H1b;HIST1H1B 
GeneID:3006 HIST1H1C histone 1, H1c;HIST1H1C 
GeneID:3024 HIST1H1A histone 1, H1a;HIST1H1A 
GeneID:8337 HIST2H2AA histone 2, H2aa;HIST2H2AA 
GeneID:8334 HIST1H2AC histone 1, H2ac;HIST1H2AC 
GeneID:3013 HIST1H2AD histone 1, H2ad;HIST1H2AD 
GeneID:317772 HIST2H2AB histone 2, H2ab;HIST2H2AB 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
GeneID:8091 HMGA2 high mobility group AT-hook 2;HMGA2 
GeneID:171017 ZNF384 zinc finger protein 384;ZNF384 
GeneID:3159 HMGA1 high mobility group AT-hook 1;HMGA1 
GeneID:154790 CLEC2L C-type lectin domain family 2, member L;CLEC2L 
   
Protein metabolism and modification (BP00060) 54 
GeneID:6125 RPL5 ribosomal protein L5;RPL5 
GeneID:6132 RPL8 ribosomal protein L8;RPL8 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:2288 FKBP4 FK506 binding protein 4, 59kDa;FKBP4 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:7314 UBB ubiquitin B;UBB 
GeneID:10277 UBE4B ubiquitination factor E4B (UFD2 homolog, yeast);UBE4B 
GeneID:1915 EEF1A1 eukaryotic translation elongation factor 1 alpha 1;EEF1A1 
GeneID:3190 HNRPK heterogeneous nuclear ribonucleoprotein K;HNRPK 
GeneID:3303 HSPA1A heat shock 70kDa protein 1A;HSPA1A 
GeneID:51773 HBXAP hepatitis B virus x associated protein;HBXAP 
GeneID:8672 EIF4G3 eukaryotic translation initiation factor 4 gamma, 3;EIF4G3 
GeneID:9531 BAG3 BCL2-associated athanogene 3;BAG3 
GeneID:6124 RPL4 ribosomal protein L4;RPL4 
GeneID:3326 HSPCB heat shock 90kDa protein 1, beta;HSPCB 
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GeneID:1917 EEF1A2 eukaryotic translation elongation factor 1 alpha 2;EEF1A2 
GeneID:6203 RPS9 ribosomal protein S9;RPS9 
GeneID:6128 RPL6 ribosomal protein L6;RPL6 
GeneID:6202 RPS8 ribosomal protein S8;RPS8 
GeneID:6138 RPL15 ribosomal protein L15;RPL15 
GeneID:6129 RPL7 ribosomal protein L7;RPL7 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:6139 RPL17 ribosomal protein L17;RPL17 
GeneID:142 PARP1 poly (ADP-ribose) polymerase family, member 1;PARP1 
GeneID:826 CAPNS1 calpain, small subunit 1;CAPNS1 
GeneID:3320 HSPCA heat shock 90kDa protein 1, alpha;HSPCA 
GeneID:3312 HSPA8 heat shock 70kDa protein 8;HSPA8 
GeneID:5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide;PRKDC 
GeneID:4293 MAP3K9 mitogen-activated protein kinase kinase kinase 9;MAP3K9 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:6187 RPS2 ribosomal protein S2;RPS2 
GeneID:3324 HSPCA heat shock 90kDa protein 1, alpha-like 3;HSPCAL3 
GeneID:10038 PARP2 poly (ADP-ribose) polymerase family, member 2;PARP2 
GeneID:6141 RPL18 ribosomal protein L18;RPL18 
GeneID:6136 RPL12 ribosomal protein L12;RPL12 
GeneID:6135 RPL11 ribosomal protein L11;RPL11 
GeneID:6143 RPL19 ribosomal protein L19;RPL19 
GeneID:51187 RPL24 chromosome 15 open reading frame 15;C15orf15 
GeneID:9349 RPL17 ribosomal protein L23;RPL23 
GeneID:6154 RPL26 ribosomal protein L26;RPL26 
GeneID:6208 RPS14 ribosomal protein S14;RPS14 
GeneID:6205 RPS11 ribosomal protein S11;RPS11 
GeneID:6204 RPS10 ribosomal protein S10;RPS10 
GeneID:6223 RPS19 ribosomal protein S19;RPS19 
GeneID:6229 RPS24 ribosomal protein S24;RPS24 
GeneID:6152 RPL24 ribosomal protein L24;RPL24 
GeneID:6155 RPL27 ribosomal protein L27;RPL27 
GeneID:6159 RPL29 ribosomal protein L29;RPL29 
GeneID:6160 RPL31 ribosomal protein L31;RPL31 
GeneID:6181 RPLP2 ribosomal protein, large, P2;RPLP2 
GeneID:6156 RPL30 ribosomal protein L30;RPL30 
GeneID:6176 RPLP1 ribosomal protein, large, P1;RPLP1 
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GeneID:6228 RPS23 ribosomal protein S23;RPS23 
GeneID:6217 RPS16 ribosomal protein S16;RPS16 
   
Cell cycle (BP00203) 29   
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:2288 FKBP4 FK506 binding protein 4, 59kDa;FKBP4 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:7155 TOP2B topoisomerase (DNA) II beta 180kDa;TOP2B 
GeneID:3065 HDAC1 histone deacetylase 1;HDAC1 
GeneID:8243 SMC1L1 SMC1 structural maintenance of chromosomes 1-like 1 (yeast);SMC1L1 
GeneID:51773 HBXAP hepatitis B virus x associated protein;HBXAP 
GeneID:7486 WRN Werner syndrome;WRN 
GeneID:7278 TUBA2 tubulin, alpha 2;TUBA2 
GeneID:4673 NAP1L1 nucleosome assembly protein 1-like 1;NAP1L1 
GeneID:7153 TOP2A topoisomerase (DNA) II alpha 170kDa;TOP2A 
GeneID:51807 TUBA8 tubulin, alpha 8;TUBA8 
GeneID:6118 RPA2 replication protein A2, 32kDa;RPA2 
GeneID:3066 HDAC2 histone deacetylase 2;HDAC2 
GeneID:4172 MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae);MCM3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:253959 GARNL1 GTPase activating Rap/RanGAP domain-like 1;GARNL1 
GeneID:59 ACTA2 actin, alpha 2, smooth muscle, aorta;ACTA2 
GeneID:10376 K-ALPHA-1 tubulin, alpha, ubiquitous;K-ALPHA-1 
GeneID:84790 TUBA6 tubulin, alpha 6;TUBA6 
GeneID:5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide;PRKDC 
GeneID:7150 TOP1 topoisomerase (DNA) I;TOP1 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:70 ACTC actin, alpha, cardiac muscle;ACTC 
GeneID:6117 RPA1 replication protein A1, 70kDa;RPA1 
GeneID:1069 CETN2 centrin, EF-hand protein, 2;CETN2 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
GeneID:8091 HMGA2 high mobility group AT-hook 2;HMGA2 
GeneID:3159 HMGA1 high mobility group AT-hook 1;HMGA1 
   
Apoptosis (BP00179) 17   
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GeneID:57099 AVEN apoptosis, caspase activation inhibitor;AVEN 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10277 UBE4B ubiquitination factor E4B (UFD2 homolog, yeast);UBE4B 
GeneID:3065 HDAC1 histone deacetylase 1;HDAC1 
GeneID:9531 BAG3 BCL2-associated athanogene 3;BAG3 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:4673 NAP1L1 nucleosome assembly protein 1-like 1;NAP1L1 
GeneID:3190 HNRPK heterogeneous nuclear ribonucleoprotein K;HNRPK 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:3066 HDAC2 histone deacetylase 2;HDAC2 
GeneID:6949 TCOF1 Treacher Collins-Franceschetti syndrome 1;TCOF1 
GeneID:9513 FXR2 fragile X mental retardation, autosomal homolog 2;FXR2 
GeneID:8087 FXR1 fragile X mental retardation, autosomal homolog 1;FXR1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:2332 FMR1 fragile X mental retardation 1;FMR1 
GeneID:9131 PDCD8 programmed cell death 8 (apoptosis-inducing factor);PDCD8 
GeneID:3956 LGALS1 lectin, galactoside-binding, soluble, 1 (galectin 1);LGALS1 
   
Signal transduction (BP00102) 14 
GeneID:2288 FKBP4 FK506 binding protein 4, 59kDa;FKBP4 
GeneID:1827 DSC1 Down syndrome critical region gene 1;DSCR1 
GeneID:1823 DSC1 desmocollin 1;DSC1 
GeneID:3190 HNRPK heterogeneous nuclear ribonucleoprotein K;HNRPK 
GeneID:301 ANXA1 annexin A1;ANXA1 
GeneID:5144 PDE4D phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila);PDE4D 
GeneID:813 CALU calumenin;CALU 
GeneID:116984 CENTD1 centaurin, delta 1;CENTD1 
GeneID:396 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha;ARHGDIA 
GeneID:55114 ARHGAP17 Rho GTPase activating protein 17;ARHGAP17 
GeneID:826 CAPNS1 calpain, small subunit 1;CAPNS1 
GeneID:1825 DSC1 desmocollin 3;DSC3 
GeneID:4293 MAP3K9 mitogen-activated protein kinase kinase kinase 9;MAP3K9 
GeneID:1069 CETN2 centrin, EF-hand protein, 2;CETN2 
   
Cell structure and motility (BP00285) 13 
GeneID:301 ANXA1 annexin A1;ANXA1 
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GeneID:7278 TUBA2 tubulin, alpha 2;TUBA2 
GeneID:51807 TUBA8 tubulin, alpha 8;TUBA8 
GeneID:116984 CENTD1 centaurin, delta 1;CENTD1 
GeneID:59 ACTA2 actin, alpha 2, smooth muscle, aorta;ACTA2 
GeneID:7431 VIM vimentin;VIM 
GeneID:10376 K-ALPHA-1 tubulin, alpha, ubiquitous;K-ALPHA-1 
GeneID:55114 ARHGAP17 Rho GTPase activating protein 17;ARHGAP17 
GeneID:84790 TUBA6 tubulin, alpha 6;TUBA6 
GeneID:4293 MAP3K9 mitogen-activated protein kinase kinase kinase 9;MAP3K9 
GeneID:70 ACTC actin, alpha, cardiac muscle;ACTC 
GeneID:2670 GFAP glial fibrillary acidic protein;GFAP 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
   
Developmental processes (BP00193) 13 
GeneID:2626 GATA4 GATA binding protein 4;GATA4 
GeneID:3980 LIG3 ligase III, DNA, ATP-dependent;LIG3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:1827 DSC1 Down syndrome critical region gene 1;DSCR1 
GeneID:8243 SMC1L1 SMC1 structural maintenance of chromosomes 1-like 1 (yeast);SMC1L1 
GeneID:51773 HBXAP hepatitis B virus x associated protein;HBXAP 
GeneID:7486 WRN Werner syndrome;WRN 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:2956 MSH6 mutS homolog 6 (E. coli);MSH6 
GeneID:6949 TCOF1 Treacher Collins-Franceschetti syndrome 1;TCOF1 
GeneID:7431 VIM vimentin;VIM 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
   
Immunity and defense (BP00148) 13 
GeneID:2288 FKBP4 FK506 binding protein 4, 59kDa;FKBP4 
GeneID:4293 MAP3K9 mitogen-activated protein kinase kinase kinase 9;MAP3K9 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:3303 HSPA1A heat shock 70kDa protein 1A;HSPA1A 
GeneID:7520 XRCC5 
X-ray repair complementing defective repair in Chinese 
hamster cells 5 (double-strand-break rejoining; Ku 
autoantigen, 80kDa);XRCC5 
GeneID:2547 G22P1 X-ray repair complementing defective repair in Chinese 
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hamster cells 6 (Ku autoantigen, 70kDa);XRCC6 
GeneID:3326 HSPCB heat shock 90kDa protein 1, beta;HSPCB 
GeneID:142 PARP1 poly (ADP-ribose) polymerase family, member 1;PARP1 
GeneID:3320 HSPCA heat shock 90kDa protein 1, alpha;HSPCA 
GeneID:3312 HSPA8 heat shock 70kDa protein 8;HSPA8 
GeneID:3324 HSPCA heat shock 90kDa protein 1, alpha-like 3;HSPCAL3 
GeneID:10038 PARP2 poly (ADP-ribose) polymerase family, member 2;PARP2 
GeneID:3956 LGALS1 lectin, galactoside-binding, soluble, 1 (galectin 1);LGALS1 
   
Intracellular protein traffic (BP00125) 10 
GeneID:3190 HNRPK heterogeneous nuclear ribonucleoprotein K;HNRPK 
GeneID:7278 TUBA2 tubulin, alpha 2;TUBA2 
GeneID:51807 TUBA8 tubulin, alpha 8;TUBA8 
GeneID:253959 GARNL1 GTPase activating Rap/RanGAP domain-like 1;GARNL1 
GeneID:59 ACTA2 actin, alpha 2, smooth muscle, aorta;ACTA2 
GeneID:10376 K-ALPHA-1 tubulin, alpha, ubiquitous;K-ALPHA-1 
GeneID:84790 TUBA6 tubulin, alpha 6;TUBA6 
GeneID:70 ACTC actin, alpha, cardiac muscle;ACTC 
GeneID:4678 NASP nuclear autoantigenic sperm protein (histone-binding);NASP 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
   
Cell proliferation and differentiation (BP00224) 5 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:51773 HBXAP hepatitis B virus x associated protein;HBXAP 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:1069 CETN2 centrin, EF-hand protein, 2;CETN2 
   
Transport (BP00141) 5   
GeneID:59 ACTA2 actin, alpha 2, smooth muscle, aorta;ACTA2 
GeneID:9513 FXR2 fragile X mental retardation, autosomal homolog 2;FXR2 
GeneID:8087 FXR1 fragile X mental retardation, autosomal homolog 1;FXR1 
GeneID:70 ACTC actin, alpha, cardiac muscle;ACTC 
GeneID:2332 FMR1 fragile X mental retardation 1;FMR1 
   
Nitrogen metabolism (BP00090) 4 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
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Table 3.7 Listing of  all complex proteins in each of the 14 pathways 
p53 pathway (P00059) 9   
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:8850 PCAF p300/CBP-associated factor;PCAF 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
   
Cell adhesion (BP00124) 4 
GeneID:1823 DSC1 desmocollin 1;DSC1 
GeneID:116984 CENTD1 centaurin, delta 1;CENTD1 
GeneID:1825 DSC1 desmocollin 3;DSC3 
GeneID:3956 LGALS1 lectin, galactoside-binding, soluble, 1 (galectin 1);LGALS1 
   
Biological process unclassified (BP00216) 3 
GeneID:9774 BCLAF1 BCL2-associated transcription factor 1;BCLAF1 
GeneID:128312 HIST3H2BB histone 3, H2bb;HIST3H2BB 
GeneID:6119 RPA3 replication protein A3, 14kDa;RPA3 
   
Neuronal activities (BP00166) 2 
GeneID:2288 FKBP4 FK506 binding protein 4, 59kDa;FKBP4 
GeneID:2521 FUS fusion (involved in t(12;16) in malignant liposarcoma);FUS
   
Oncogenesis (BP00281) 3   
GeneID:2521 FUS fusion (involved in t(12;16) in malignant liposarcoma);FUS
GeneID:286514 MAGEB18 melanoma antigen family B, 18;MAGEB18 
   
Muscle contraction (BP00173) 1 
GeneID:1152 CKB creatine kinase, brain;CKB 
   
Lipid, fatty acid and steroid metabolism (BP00019) 1 
GeneID:301 ANXA1 annexin A1;ANXA1 
   
Sensory perception (BP00182) 1 
GeneID:6949 TCOF1 Treacher Collins-Franceschetti syndrome 1;TCOF1 
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GeneID:3065 HDAC1 histone deacetylase 1;HDAC1 
GeneID:7486 WRN Werner syndrome;WRN 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:3066 HDAC2 histone deacetylase 2;HDAC2 
GeneID:5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide;PRKDC 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
   
Apoptosis signaling pathway (P00006) 7 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:3303 HSPA1A heat shock 70kDa protein 1A;HSPA1A 
GeneID:9531 BAG3 BCL2-associated athanogene 3;BAG3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:3312 HSPA8 heat shock 70kDa protein 8;HSPA8 
GeneID:9131 PDCD8 programmed cell death 8 (apoptosis-inducing factor);PDCD8 
   
p53 pathway feedback loops 2 (P04398) 5 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide;PRKDC 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
   
Huntington disease (P00029) 5 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:826 CAPNS1 calpain, small subunit 1;CAPNS1 
GeneID:8655 DNCL1 dynein, light chain, LC8-type 1;DYNLL1 
   
Wnt signaling pathway (P00057) 5 
GeneID:3065 HDAC1 histone deacetylase 1;HDAC1 
GeneID:6597 SMARCA4 SWI/SNF related, matrix associated, actin dependent 
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regulator of chromatin, subfamily a, member 4;SMARCA4 
GeneID:8467 SMARCA5 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5;SMARCA5 
GeneID:3066 HDAC2 histone deacetylase 2;HDAC2 
GeneID:6596 SMARCA3 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 3;SMARCA3 
   
FAS signaling pathway (P00020) 5 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:142 PARP1 poly (ADP-ribose) polymerase family, member 1;PARP1 
GeneID:10038 PARP2 poly (ADP-ribose) polymerase family, member 2;PARP2 
   
Insulin/IGF pathway-protein kinase B signaling cascade (P00033) 4 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:253959 GARNL1 GTPase activating Rap/RanGAP domain-like 1;GARNL1 
   
EGF receptor signaling pathway (P00018) 4 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
   
DNA replication (P00017) 4 
GeneID:7155 TOP2B topoisomerase (DNA) II beta 180kDa;TOP2B 
GeneID:7153 TOP2A topoisomerase (DNA) II alpha 170kDa;TOP2A 
GeneID:6118 RPA2 replication protein A2, 32kDa;RPA2 
GeneID:7150 TOP1 topoisomerase (DNA) I;TOP1 
   
Angiogenesis (P00005) 3   
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
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Interleukin signaling pathway (P00036) 3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
Inflammation mediated by chemokine and cytokine signaling pathway (P00031) 3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
Hypoxia response via HIF activation (P00030) 3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
Endothelin signaling pathway (P00019) 3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
PI3 kinase pathway (P00048) 3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
PDGF signaling pathway (P00047) 3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
Ras Pathway (P04393) 3   
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
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GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
VEGF signaling pathway (P00056) 3 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
T cell activation (P00053) 3   
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
FGF signaling pathway (P00021) 3 
GeneID:10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma);AKT3 
GeneID:207 AKT1 v-akt murine thymoma viral oncogene homolog 1;AKT1 
GeneID:208 AKT2 v-akt murine thymoma viral oncogene homolog 2;AKT2 
   
Parkinson disease (P00049) 2 
GeneID:3303 HSPA1A heat shock 70kDa protein 1A;HSPA1A 
GeneID:3312 HSPA8 heat shock 70kDa protein 8;HSPA8 
   
Oxidative stress response (P00046) 1 
GeneID:2521 FUS fusion (involved in t(12;16) in malignant liposarcoma);FUS 
   
Notch signaling pathway (P00045) 1 







Table 3.8 Complex proteins involving in mRNA transcription, DNA repair 
and DNA replication 
 
mRNA transcription (BP00040) 30 
GeneID:84717 HDGF2 hepatoma-derived growth factor-related protein 2;HDGF2 
GeneID:1107 CHD3 chromodomain helicase DNA binding protein 3;CHD3 
GeneID:50810 HDGF2 hepatoma-derived growth factor, related protein 3;HDGFRP3 
GeneID:3065 HDAC1 histone deacetylase 1;HDAC1 
GeneID:7155 TOP2B topoisomerase (DNA) II beta 180kDa;TOP2B 
GeneID:8850 PCAF p300/CBP-associated factor;PCAF 
GeneID:51773 HBXAP hepatitis B virus x associated protein;HBXAP 
GeneID:3190 HNRPK heterogeneous nuclear ribonucleoprotein K;HNRPK 
GeneID:8467 SMARCA5 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 
5;SMARCA5 
GeneID:1106 CHD2 chromodomain helicase DNA binding protein 2;CHD2 
GeneID:6664 SOX11 SRY (sex determining region Y)-box 11;SOX11 
GeneID:6597 SMARCA4 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 
4;SMARCA4 
GeneID:7153 TOP2A topoisomerase (DNA) II alpha 170kDa;TOP2A 
GeneID:23429 RYBP RING1 and YY1 binding protein;RYBP 
GeneID:3066 HDAC2 histone deacetylase 2;HDAC2 
GeneID:51087 YBX2 Y box binding protein 2;YBX2 
GeneID:4204 MECP2 methyl CpG binding protein 2 (Rett syndrome);MECP2 
GeneID:8531 CSDA cold shock domain protein A;CSDA 
GeneID:7150 TOP1 topoisomerase (DNA) I;TOP1 
GeneID:6749 SSRP1 structure specific recognition protein 1;SSRP1 
GeneID:6596 SMARCA3 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 
3;SMARCA3 
GeneID:57459 GATAD2B GATA zinc finger domain containing 2B;GATAD2B 
GeneID:80314 EPC1 enhancer of polycomb homolog 1 (Drosophila);EPC1 
GeneID:4904 NSEP1,YBX1 Y box binding protein 1;YBX1 
GeneID:2626 GATA4 GATA binding protein 4;GATA4 
GeneID:9406 ZNF265 zinc finger protein 265;ZNF265 
GeneID:8091 HMGA2 high mobility group AT-hook 2;HMGA2 
GeneID:171017 ZNF384 zinc finger protein 384;ZNF384 
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GeneID:3159 HMGA1 high mobility group AT-hook 1;HMGA1 
GeneID:154790 CLEC2L C-type lectin domain family 2, member L;CLEC2L 
   
DNA repair (BP00036) 16 
GeneID:27301 APEX2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2;APEX2 
GeneID:5886 RAD23A RAD23 homolog A (S. cerevisiae);RAD23A 
GeneID:8243 SMC1L1 SMC1 structural maintenance of chromosomes 1-like 1 (yeast);SMC1L1 
GeneID:6118 RPA2 replication protein A2, 32kDa;RPA2 
GeneID:7508 XPC xeroderma pigmentosum, complementation group C;XPC 
GeneID:7520 XRCC5 
X-ray repair complementing defective repair in 
Chinese hamster cells 5 (double-strand-break 
rejoining; Ku autoantigen, 80kDa);XRCC5 
GeneID:5887 RAD23B RAD23 homolog B (S. cerevisiae);RAD23B 
GeneID:2956 MSH6 mutS homolog 6 (E. coli);MSH6 
GeneID:2547 G22P1 
X-ray repair complementing defective repair in 
Chinese hamster cells 6 (Ku autoantigen, 
70kDa);XRCC6 
GeneID:142 PARP1 poly (ADP-ribose) polymerase family, member 1;PARP1 
GeneID:10038 PARP2 poly (ADP-ribose) polymerase family, member 2;PARP2 
GeneID:23049 SMG1 PI-3-kinase-related kinase SMG-1;SMG1 
GeneID:5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide;PRKDC 
GeneID:3980 LIG3 ligase III, DNA, ATP-dependent;LIG3 
GeneID:7507 XPA xeroderma pigmentosum, complementation group A;XPA 
GeneID:1069 CETN2 centrin, EF-hand protein, 2;CETN2 
   
DNA replication (BP00035) 8 
GeneID:7155 TOP2B topoisomerase (DNA) II beta 180kDa;TOP2B 
GeneID:7486 WRN Werner syndrome;WRN 
GeneID:4673 NAP1L1 nucleosome assembly protein 1-like 1;NAP1L1 
GeneID:7153 TOP2A topoisomerase (DNA) II alpha 170kDa;TOP2A 
GeneID:6118 RPA2 replication protein A2, 32kDa;RPA2 
GeneID:4172 MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae);MCM3 
GeneID:7150 TOP1 topoisomerase (DNA) I;TOP1 

























              Post-translational modification (PTM) constitutes an important 
mechanism for modulating protein function. There are more than 200 
described protein PTMs that vary from well-studied (e.g. phosphorylation) to 
those which are poorly understood (Krishna and Wold, 1993). More and more 
modifications have been discovered that they can impact the stability, 
interactions, biochemical activity and localization of proteins.  
              Lysine acetylation, or the transfer of an acetyl group from acetyl 
coenzyme A to the ε-amino group of a lysine residue, is a reversible and 
highly regulated posttranslational modification. It was initially discovered on 
histones about four decades ago (Vidali et al., 1968). It has been hypothesized 
that histone acetylation forms the histone code, a complex modification 
language that is fundamental to the regulation of chromatin structure and 
function (Strahl and Allis, 2000; Turner, 2000). It also regulates other nuclear 
processes such as DNA replication, recombination and repair. 
However, it took another 30 years to identify the first nonhistone 
protein, p53, to be lysine acetylated (Gu, W. and Roeder, 1997) in 1997.  
Intensive research during the past decade has shown that acetylation is a 
common posttranslational modification and plays important roles in regulating 
the functions of eukaryotic and even viral and bacterial proteins (Kouzarides, 
2000; Sterner and Berger, 2000). So far, about 40 transcription factors and 
over 30 other proteins have been described that can be acetylated by histone 
acetyltransferases (HATs) (Polevoda and Sherman, 2002; Yang, 2004; 
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Drummond et al., 2005). A more recent research applied a proteomic survey 
and identified 195 lysine-acetylated proteins derived from HeLa cells and 
mouse liver mitochondria (Kim, S. C. et al., 2006). The modification regulates 
diverse protein properties including chromatin dynamics and transcription 
(Kuo and Allis, 1998; Knoepfler and Eisenman, 1999; Kouzarides, 1999; 
Wolffe and Guschin, 2000), gene silencing (Bestor, 1998; Razin, 1998), cell 
cycle progression (Marzio et al., 2000; Morris et al., 2000; Takahashi et al., 
2000; Zhang et al., 2000), apoptosis (Fu et al., 2004; Iyer et al., 2004; Roh et 
al., 2004), differentiation (Koipally et al., 1999; Wang, A. H. et al., 1999; 
Zhou et al., 2000; Miska et al., 2001; Sartorelli and Puri, 2001), DNA 
replication (Iizuka and Stillman, 1999; Aggarwal and Calvi, 2004), DNA 
repair (Gu, W. and Roeder, 1997; Sakaguchi et al., 1998; Liu et al., 1999; 
Abraham et al., 2000; Rubbi and Milner, 2003; Bernardi et al., 2004), nuclear 
import (Blander et al., 2002; Madison et al., 2002; Gay et al., 2003), neuronal 
repression (Huang et al., 1999; Roopra et al., 2000; Boutillier et al., 2003) and 
protein stability (Caron et al., 2005). In addition to its important roles in 
fundamental biology, lysine acetylation is also intimately linked to aging and 
several major diseases such as cancer, neurodegenerative disorders, and 
cardiovascular diseases (Carrozza et al., 2003; Blander and Guarente, 2004; 
McKinsey and Olson, 2004; Yang, 2004). 
              Acetylation is reversible in vivo. The reactions are catalysed by 
histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs 
transfer acetyl groups from acetyl-coenzyme A (AcCoA) to the ε-amino group 
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of specific lysines of substrate proteins while HDACs remove acetyl groups 
from specific acetyl-lysine residues in their substrates. HDACs can be 
suppressed by HDAC inhibitors through which HDACs inhibitors can result in 
protein acetylation indirectly (Johnstone and Licht, 2003). More than 20 
acetyltransferases and 18 deacetylases have been identified so far 
(Marmorstein and Roth, 2001; Thiagalingam et al., 2003), but the mechanism 
of substrate selection and site specificity of these enzymes are still unknown. 
Interestingly, one substrate can interact and be acetylated by multiple 
acetyltransferases. How these HATs and HDACs interact with transcription 
factors and other non-histone proteins will be continuously proceeding in the 
coming few years. Because of the critical role of acetylation in the regulation 
of oncogenic processes, HDAC inhibitors have been developed as therapeutic 
agents for both hematologic malignancies and solid tumors (Egger et al., 
2004). 
Many techniques have been described to determine the presence of 
PTMs. Most of the known acetylated proteins have been identified by 
radioactive analysis or immuno detection. However, both radioactive analysis 
and immuno detection only provide evidence for acetylation but will not 
provide information about the number and location of acetylation sites in a 
protein. In recent years, the analysis of protein acetylation by mass 
spectrometry (MS) has become more and more popular since MALDI TOF 
MS and ESI MS provide fast and sensitive methods for the characterization of 
posttranslational modifications (Wilkins et al., 1999; Mann and Jensen, 2003; 
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McDonald and Yates, 2003). Mass spectrometric measurement of the 
molecular weight of in vivo or in vitro acetylated proteins can reveal the 
number and locations of acetyl groups attached to the protein besides the 
normal characterization. Since the signal of an acetylated protein or peptide is 
shifted by +42 Da per covalently bound acetyl group as compared to the signal 
of the unmodified protein or peptide, the number of acetylation sites in a 
protein can easily be determined by MS. 
Ku70 is one of the proteins that can be acetylated by HAT.  Five lysine 
residues in C terminal (539, 542, 544, 553, and 556) were reported to be 
acetylated by CBP and PCAF. Both Class I/II HDACs and Class III HDACs 
target Ku70 in vivo. A model was proposed that the acetylation of C terminal 
of Ku70 will release Bax from Ku70 thus activates the apoptosis process. 
Moreover, inhibition of HDAC activity by using TSA (class I and II HDACs 
inhibitor) and nicotinamide (class III HDACs inhibitor), results in increased 
acetylation of these residues , suggesting that the acetylation status of these 
same residues is also determined by HDACs . The similar result was 
demonstrated in NB cells.  
              Here we incubated Ku70 with two HATs, PCAF and p300, to induce 
the in vitro acetylation of Ku70 and employed MS to detect the acetylation site 
of Ku70 as well as the in vivo acetylation.  
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4.2 Materials and Methods 
4.2.1 Plasmid Constructions 
              The Ku70 cDNA was amplified using the following oligonucleotides 
as primers for the PCR: forward primer 5’ CTGTAGACATATGATGTCAGG 
GTGGGAGTC 3’ and reverse primer 5’ GATCGCTCACGCGGCCGCGTCC 
TGGAAGTGCT 3’ which introduce a NdeI cutting site into the 5’ terminal of 
Ku70 cDNA and a NotI cutting site into the 3’terminal of Ku70 cDNA. PCR 
product was purified from the gel (QIAquick Gel Extraction Kit, Qiagen, 
Germany) and double digested by NdeI and NotI. The digested PCR product 
was purified (QIAquick PCR Purification Kit, Qiagen, Germany) and cloned 
into the NdeI and NotI sites of pET42b (Novagen, Germany) in frame to 
generate pET42b-Chis-Ku70 which will produce Ku70 with a 6×His tag in its 
C terminal. 
 
4.2.2 Protein Expression 
              The plasmid was transformed and expressed in BL21. The Correct 
integration of constructs was verified by colony PCR. 
 
4.2.3 Time Course Analysis of Protein Expression 
              The correct colony was picked to inoculate a small amount of culture 
medium containing Kanamycin (50ug/ml) in a 15 ml tube and grew at 37°C 
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overnight. The overnight cultures were used to inoculate 100 ml media (with 
antibiotics) and grew at 37°C with vigorous shaking until an OD600 of 0.6 was 
reached. IPTG was added to induce expression to a final concentration of 
1mM. The cultures were incubated for an additional 5 hours. Small amount of 
sample were collected at time points 0h, 1h, 2h, 3h, 4h,5h as well as a control 
which was incubated without induction by IPTG. Samples were spinned down 
and dissolved in 20ul 2×SDS loading dye and ready for electrophoresis.  
 
4.2.4 Determination of Target Protein Solubility 
              E.Coli cell pellet was resuspended in 5ml of lysis buffer for native 
purification (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10 mM β-
mecapitethanol, 0.5mM PMSF, pH8.0).  Lysozyme was added to 1mg/ml and 
incubated on ice for 30 min.  The lysates were then sonicated 6×10s with 10s 
pauses at 200-300 W and centrifuged at 10000g at 4°C for 20-30 mins. The 
supernatant and pellet were separated for electrophoresis. 
 
4.2.5 Protein Purification 
              A Ni-NTA resin was added into a Poly-Prep column (Bio-Rad) and 
equilibrated by washing with 2×5 volumes of lysis buffer. Cleared cell lysate 
was added to Ni-NTA resin and mixed gently by shaking (200 rpm on a rotary 
shaker) at 4°C for 2h. The resin was washed by 2×5 volumes of wash buffer 1 
(50 mM NaH2PO4, 300 mM NaCl, 40 mM imidazole, 0.5%TritonX-100, 10% 
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glycerol, 10 mM β-mecapitethanol, complete EDTA-free protease, 0.5 mM 
PMSF, pH 8.0) followed by 3×5 volume of wash buffer 2 (50 mM NaH2PO4, 
1M NaCl, 40 mM imidazole, 0.5%TritonX-100, 10% glycerol, 10 mM β-
mecapitethanol, complete EDTA-free protease inhibitor, 0.5 mM PMSF, pH 
8.0) and 2×5 volume of wash buffer 1. The protein was eluted three times with 
3 volumes of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 350 mM 
imidazole, pH 8.0) for each time and incubated for 10 minutes.  The purified 
Ku70 was quantified with  Bradford method.  
 
4.2.6 In Vitro Acetylation 
4.2.6.1 PCAF Induced In Vitro Acetylation 
10μg purified Ku70, 500ng PCAF, active (Upstate), 1nM Acetyl CoA 
and  5X HAT assay buffer (250mM Tris-HCl, pH 8.0, 0.5mM EDTA, 50% 
glycerol) were added into a tube. The whole system was top up to 50μl with 
sterile water and incubated in a 30°C shaking incubator for 60 minutes. 
 
4.2.6.2 P300 Induced In Vitro Acetylation 
10μg purified Ku70, 2μg p300 HAT domain (Upstate), 1nM Acetyl 
CoA and  5X HAT assay buffer (250mM Tris-HCl, pH 8.0, 0.5mM EDTA, 
50% glycerol) were added into a tube. The whole system was top up to 30μl 
with sterile water and incubated in a 30°C shaking incubator for 60 minutes. 
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4.2.7 SDS-polyacrylamide Gel Electrophoresis (SDS-PAGE)  and Western 
Blot 
The purity of Ku70 was verified by SDS-polyacrylamide gel 
electrophoresis and the acetylation of Ku70 was verified by Western blotting. 
Anti-acetyl-lysine antibody (Cell Signaling) was used as primary antibody. 
 
4.2.8 Simply Blue Staining 
After electrophoresis, the gels were stained in Simply Blue solution 
(Invitrogen) by microwave method according to the manufacturer’s 
instructions. The gel was then destained by MilliQ water until the background 
of the gel was no longer bluish. 
 
4.2.9 Treatment of  293F Cells by HDAC Inhibitors 
293F cells expressing TAP-tagged Ku70 were treated by 1μM TSA, 5 
μM SAHA and 5mM nicotinamide respectively for 24h. Cells were then 
collected. Cell lysates were purified by TAP-tag purification. 
 
4.2.10 Sample Preparation for Mass Spectrometry 
  The solution containing acetylated Ku70 was reduced by 10mM DTT , 
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alkylated by 20mM IAA and digested by trypsin at the ratio of 1:50 
(trypsin:protein) overnight (12-16h) at 37°C. After digestion, 0.1% TFA was 
added to terminate the reaction. The resulting peptides were sequenced by 
tandem mass spectrometry (LC-MS/MS). 
 
4.2.11 Mass Spectrometry Analysis 
  For LC-MS/MS, samples were analyzed with a Finnigan Surveyor 
HPLC system coupled online to a LTQ ion trap mass spectrometer (Thermo 
Electron, San Jose, CA) equipped with nano-ESI source. A C18 nanocolumn 
(i.d. 75 μm, length 100 mm, tip 15 μm, New Objectives, Woburn, MA) was 
packed with Magic C18 particles (particle size 5 μm, pore size 300 Å, 
Michrom BioResources, Auburn, CA). The flow rate through the column was 
200 nL/min. A water-acetonitrile gradient was employed with both mobile 
phases containing 0.1% formic acid. The gradient used was 5%-50% 
acetonitrile over 60 min. The injection volume was 100 μL. The electrospray 
mass spectra were acquired at a voltage of 1.8 kV, ion transfer tube 
temperature of 180 °C, collision gas pressure of 0.85 mTorr and normalized 
collision energy of 35% for MS2. Ion selection threshold was set to 500 counts 
for initiating MS2 while activation q was set to 0.25 and activation time to 30 
ms.  The MS scan range was  200 - 2000 m/z and mass spectra were collected 
in data-dependent MS2 mode in which five of the highest intensity peaks in 
each MS scan were chosen for CID, with an isolation width of 3 Da.  
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4.2.12 Data Analysis  
  MS/MS data were analyzed by MASCOT (Matrix Science, London) 
database search engine searching against IPI human database. Database search 
was performed with carbaminomethylation (Cys) set as fixed modification, 
oxidized methionine (+16 Da) and acetylation as viable modifications. Missed 
cleavages of trypsin were set to two. Peptide charges were confined to 1+, 2+ 
and 3+ and mass tolerance were set to 2.0 Da for peptide and 0.8 Da for 
fragment ions, respectively. 
 
4.3 Results 
4.3.1 Optimization of Protein Expression 
BL21 cells were incubated for different time after induction by IPTG. 
Small amount of samples were collected at each time point for electrophoresis 
analysis. BL21 expressing Ku70 was lysed by lysis buffer for native 
purification. Supernatant and pellet were collected to determine the solubility 
of Ku70. As shown in Figure 4.1, Ku70 was induced to overexpress after the 
addition of IPTG. We found 5h is efficient for the expression of Ku70. 
Although most of Ku70 were still in the pellet, there are still soluble Ku70 in 
the supernatant. Exogenous Ku70 may form inclusion body in BL21 and are 
insoluble in lysis buffer for native purification. 
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Figure 4.1  
 
A. Time course analysis of protein expression 
BL21 was induced by IPTG after an OD600 of 0.6 was reached. The cultures 
were incubated for an additional 5 hours. Small amount of sample were 
collected at timepoints 0h, 1h, 2h, 3h, 4h,5h as well as a control which was 
incubated without induction by IPTG. 
 
B. Determination of Ku70 solubility in BL21 
BL21 expressing his-tagged Ku70 was lysed by lysis buffer for native 
purification. The supernatant and pellet were separated for electrophoresis. 
1, Supernatant for soluble proteins. 2, pellet for insoluble proteins. 
 
C. Purification of His-tagged Ku70 on Ni-NTA matrices 
BL21 was lysed by lysis buffer for native purification. The supernatant was 




4.3.2 Purification of His-tagged Ku70 
The His-tagged Ku70 was purified on Ni-NTA matrices. But the purity 
was not high. We tried to optimize the condition by adding detergents, 
increasing salt concentration or changing concentration of imidazole in 
washing buffer. But the effect was not obvious (Figure 4.1). Although Ku70 
was the predominant protein in eluate, there were still some other proteins.  
 
4.3.3 In Vitro Acetylation of Ku70 
  The purified Ku70 was incubated with histone acetyltransferases 
PCAF and p300 respectively.  PCAF and p300 are HATs that were used here 
to in-vitro acetylating Ku70.  The aceytlation was detected by anti-acetyl-
lysine antibody (Cell Signaling) (Figure 4.2, A). The acetylated Ku70 was 
then tryptic digested for mass spectrometry analysis. We repeated the 
experiments three times.  Combined with all the data, we detected 21 
acetylation sites by PCAF acetylation:  K92, K182, K206, K299, K317, K351, 
K392, K443, K445, K461, K463, K468, K516, K539, K542, K565, K570, 
K575, K582, K591, K595 and 22 acetylation sites by p300 acetylation: K74, 
K94, K100, K129, K182, K189, K260, K265, K282, K287, K297, K299, 
K317, K445, K461, K463, K539, K542, K575, K582, K591, K595.  Twelve 
lysines could be acetylated both by PCAF and p300.  Nine lysines were 
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Figure 4.2 Acetylation of Ku70 and Ku80 
 
A. His-tagged Ku70 was expressed in BL21and purified by Ni-NTA resin. 
The purified Ku70 was incubated with HATs- PCAF and p300. The 
acetylatioin was detected by anti-acetyl-lysine antibody. 
 
B. The eluate from TAP tag purification of NTAP-tagged Ku70 was separated 
by SDS-PAGE and then transferred to PVDF membrane. Anti-acetyl-lysine 
antibody was used to detected acetylated proteins. Ku80 was found to be 
acetylated according to molecular weight. 














4.3.4 In Vivo Acetylation of Ku70 
By including lysine acetylation as variable modification in Mascot 
search of TAP tag purified Ku70 from 293F cell, we found some acetylated 
lysines in vivo by endogenous acetyltransferase especially when cells were 
treated by HDAC inhibitors. Combined all the data, 19 acetylated lysine were 
found. They were K100, K245, K260, K282, K297, K299, K317, K451, K461, 
K468, K526, K539, K542, K544, K553, K556, K591, K595, and K596. 
Compared with the acetylated lysines in in vitro acetylation, 7 residues were 
novel. The comparison of in vitro and in vivo acetylation of Ku70 is shown in 
Table 4.1. 
 
4.3.5 In Vivo Acetylation of Ku80 
  The acetylation of Ku80 was also detected by western blot analysis and 
mass spectrometry analysis. The eluate from TAP tag purification of NTAP-
tagged Ku70 was separated by SDS-PAGE and then transferred to PVDF 
membrane. Anti-acetyl-lysine antibody was used to detect acetylated proteins. 
Ku80 was found to be acetylated according to its molecular weight (Figure 4.2, 
B ). The peptides of Ku80 with acetylated lysines were also detected by mass 
spectrometry. We found 14 acetylated lysines: K60, K182, K197, K208, K248, 















Table 4.1 Comparision of acetylation sites of Ku70 under in vitro, in vivo acetylation and reported acetylation sit
In vitro PCAF  92    182  206       299
  p300 74  94 100 129 182 189   260 265 282 287 297 299
In vivo      100     245 260  282  297 299
reported sites                
                 
In vitro PCAF 317   351 392 443 445  461 463 468 516  539 542
  p300 317      445  461 463    539 542
In vivo   317       451 461  468  526 539 542
reported sites 317 331 338           539 542
                 
In vitro PCAF    565 570 575 582 591 595       
  p300      575 582 591 595       
In vivo   544 553 556     591 595 596      
reported sites 544 553 556             
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4.4 Discussion 
  We first constructed a vector with His-tag at N-terminus of Ku70, but 
the purification was not good. Considering long recombinant proteins may be 
subject to premature termination and may produce a variety of truncated 
proteins, we constructed another vector placing His-tag at C-terminus of Ku70 
so that only full-length proteins are purified. Functional Ku70 is essential to 
ensure the interaction between Ku70 and HATs. Incorrect folding will lead to 
the transfiguration of the interaction domain to prevent HATs from 
recognizing Ku70. However, eukaryotic proteins expressed intracellularly in 
E.coli are frequently sequestered into insoluble inclusion bodies that lack 
functional activity. So we first checked whether Ku70 would form inclusion 
body. The result showed that most of Ku70 were insoluble and lack of 
functionality. But some fraction of Ku70 still remained in a soluble and native 
form. They could be purified by Ni-NTA matrices under native condition.  
The efficiency of His-tag purification was not ideal. Many other 
proteins were always co-purified by the nickel column. But purity was not an 
important element in our experiment. The enrichment of Ku70 would enable 
detection of more peptides and then improve the sequence coverage of the 
Ku70 protein by tandem mass spectrometry. Thus, more thorough acetylation 
sites could be discovered. The contamination by other proteins would not 
seriously affect the mass spectrometry analysis. 
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Eight lysines have been reported to be the target of HATs. They are 
K317, K331, K338, K539, K542, K544, K553 and K556. The acetylation of 
K539 and K542 are especially important for Bax-mediated apoptosis (Cohen 
et al., 2004). Except K331 and K338, all other lysines were detected by our in 
vitro and in vivo acetylation analysis. Although the peptide containing K331 
and K338 was detected by MS, acetylation was not found. Thirty-two novel 
sites were discovered totally. K299, K461, K591 and K595 were both detected 
by in vitro and in vivo acetylation. There were slight differences between in 
vitro and in vivo acetylation indicating that although soluble Ku70 in E.coli 
was functional, it might be still a little different from native Ku70 in 
mammalian cells. 
Ku80 was reported to be an acetylated protein (Cohen et al., 2004). But 
none of the acetylation sites were reported. Here we found 14 sites to be 
candidates of acetylated lysines for the first time. The sites need to be further 
validated by biochemical assays. 
 
4.5 Conclusion 
              According to our in vitro and in vivo acetylation of Ku70 and Ku80, 
we found 38 acetylated lysines in Ku70, among which 32 were novel. K299, 
K461, K591 and K595 were found to be acetylated in both in vivo and in vitro 






















Proteomics is still in its infancy stage. Innovative technology 
development is the key to advance the field to address more sophisticated 
biomedical questions. The protein sample preparation has direct and critical 
impact on the quality of mass spectrometric analysis, especially for low 
abundant protein. The current practical methods are not ideal and satisfactory 
yet.  We have presented a novel sample preparation method for desalting and 
extraction of peptides from in-solution and in-gel digestion by using a small 
piece of Empore Disk. It can consistently detect down to 10 femtomol of BSA 
in in-solution digestion and 500 femtomol BSA in in-gel digestion. For in gel 
digestion, it is possible to extract and detect down to 10 femtomole of BSA; 
however, the results vary from experiment to experiment in this low level of 
proteins.  It is not only suitable for sample preparation prior to MALDI-MS, 
but also LC-MS/MS analysis. The Empore Disk extraction minimizes the 
sample handling and transferring steps, thus reduces the losses of samples as 
well as offers a very effective and convenient tool for sample preparation. The 
procedure is simple, reproducible and economical. It is particularly suitable for 
parallel and batch samples preparation. These properties make it a useful tool 
for proteomics research.  
Besides the importance of sample preparation prior to mass 
spectrometry analysis, the quality of protein complex purification from cell 
lysate plays a decisive role in the integrity of protein-protein interactions 
research.  We have applied tandem affinity purification (TAP) method to pull 
down Ku70 complex in mammalian HEK293F cell line. This two-steps 
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protein purification technique isolated high quality Ku70 protein complex with 
minimal background. The protein complex was then identified by sensitive 
LTQ mass spectrometry. 151 proteins were found in the Ku70 complex. Most 
of them were involved in DNA repair, apoptosis, cell cycle regulation, gene 
transcription and signal transduction. Many Ku70 associated proteins 
participate in p53 pathway indicating the relationship between Ku70 and the 
development of cancer. PARP was validated to be a real Ku70 partner and 
interacted with Ku70 through Ku80. Our result provided an overview of the 
network of Ku70 in mammalian cells and clues for the roles of Ku70 in 
biological processes. We will validate and verify the roles of Ku70 in the 
apoptotic and signaling pathways by biochemical assays such as using RNAi 
technology to knock down the transcription level of Ku70.  
The acetylation of Ku70 was proven to play an important role in 
modulating Ku70 biological functions. With our in vitro and in vivo Ku70 and 
Ku80 acetylation studies, 38 acetylation lysine sites in Ku70 were identified, 
among which 32 were novel. K299, K461, K591 and K595 were identified in 
both in-vivo and in-vitro analysis.  Fourteen acetylation sites were detected in 
Ku80 for the first time. 
Our studies indicated that Ku70 is an important protein with multiple 
functions. As it may be the key protein in linking the DNA damage to cellular 
apoptosis, it may be a potential target for cancer therapy. Our future research 
will focus on the detailed study on the roles of Ku70 in linking DNA damage 
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